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 1 Summary 
 
Atopy, asthma and allergy are the most common chronic respiratory disease in 
children. There is increasing evidence suggesting the pivotal role of interactions 
between the environment and genes in the pathogenesis of these multi-factorial 
diseases. Prior linkage studies between asthma and atopy with markers on 
chromosome 5q31-33 confirmed that this region, which contains candidate genes and 
cytokine gene clusters, are associated with asthma and atopy.  
 
Earlier studies carried out by other groups members showed that specific genetic 
markers located in the chromosomes 5q31-33 region linked to asthma and atopy were 
also present in our local Chinese Singapore population. As some of these markers 
flank candidate cytokine genes, we postulate that polymorphisms found in the 
promoter or within the IL-12 and IL-13 genes as well as polymorphisms in the CD14 
gene may confer susceptibility to the asthma/atopy phenotype.  
 
Research conducted on the CD14, IL-12 and IL-13 polymorphisms, via sequencing 
and restriction length polymorphisms, showed the presence of the described 
polymorphisms in our local population. These polymorphisms however did not show 
any significant associations with total serum IgE levels or atopic disease in our local 
Chinese population. Failure to turn up any positive associations does not prove with 
certainty that these polymorphisms do not play a pivotal role in the disease severity or 
mechanisms. A few possible explanations, such as a lack of statistical power, ethnic 
diversity, different modes of diagnosis and classification (described in detail in the 
discussion), which could explain the lack of association seen between these 
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 polymorphisms and their phenotypic expression. Further work would therefore be 





 2 Introduction 
 
The morbidity and incidences of allergic asthma particularly in children are increasing 
worldwide. The role of interleukin-13 (IL-13) as one of the major players in the 
genetics of allergic diseases have been described by Graves et al [1] and Howard et al 
[2]. Various genetic studies have been carried out and results obtained have identified 
various chromosomal regions linked with allergy, asthma and atopy, and one such 
region is on chromosome 5q31-q33, where a cluster of pro-inflammatory cytokines 
reside [3]. IL-13 is one of the cytokines that have been shown to play an important 
role in the allergic inflammatory cascade.  
 
IL-13 has been known to be expressed in all forms of allergic diseases [4]. Genetic 
polymorphisms present in the IL-13 gene have shown to be associated with allergic 
asthma. The -1112 C/T variant in  the promoter region of IL-13 have been found to be 
associated with allergic asthma (p < 0.002), altered regulation of IL-13 production (p 
= 0.002) and increased binding of nuclear proteins in the Dutch population [5]. The 
Gln110Arg polymorphism in exon 4 of the IL-13 gene has been shown to be 
associated with asthma rather than IgE levels in case-control populations both from 
Britain and Japan [5].  
 
Allergic diseases such as atopy and asthma are increasingly common in Singapore, 
and the estimated number of affected individuals stand at around 140,000, with an 
average of about 100 deaths resulting from complications of the disease [6]. Not only 
is this a disturbing trend, but it also implicates economic costs. In Singapore alone, 
research into economic costs resulting from treatment of asthma were estimated at 
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 approximately US$33.93 million per annum [6]. The sum of which was made up of 
both direct and indirect costs at US$17.22 and US$16.71 million respectively [6]. It is 
definitely of worth to explore the possibilities of therapeutic and/or preventive 
strategies for the disease.  
 
2.1 Classification of atopy 
 
Atopy refers to the genetic tendency to produce immunoglobulin E (IgE) in response 
to allergens, whilst allergy per say, refers to the IgE mediated pathology arising from 
the atopic response to innocuous environmental allergens. Atopic disease can be 
expressed clinically as asthma, atopic dermatitis/eczema, urticaria, 
rhinoconjunctivities or systemic anaphylaxis. Atopic patients are assessed by the 
predisposition to synthesize and secrete immunoglobulin E (IgE) in response to 
common environmental allergens such as house dust mites, as well as allergens 
originating from the house dust mites, pollen and pets [7, 8]. In addition to genes 
controlling atopy, asthma and total serum IgE, linkage between markers are found on 
chromosome 5q31.1 [9]. Studies conducted on Danish twin pairs suggested that 73% 
of asthma susceptibility is due to genetic factors [10]. 
 
Being a multi-factorial disease with a host of cytokines and cellular factors involved 
in allergic inflammation, there has been a considerable effort made to search for 
various single nucleotide polymorphisms (SNPs) in candidate genes influencing the 
clinical expression of asthma and atopy (Table 2.1). To add to the complexity, the 
interaction of these genes and polymorphisms with environmental factors [11], have 
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 been postulated to affect final phenotypic expression, making it an intricately woven 
study. 
 
Atopy is an immune disorder best characterized by a persistent IgE mediated response 
to aeroallergens. Conventional definition of atopy has been based on one of three 
criteria’s: 1. a raised serum total IgE more than 2SD above the mean for that age; 2. a 
positive skin prick test to at least one house dust mite extract (a wheal >/3mm greater 
than negative control); and 3. the presence of positive specific IgE antibodies in the 
serum to dust mite Dermatophagoides pteronyssinus (>/class 2 or >/0.75 IU/ml) [11]. 
The disorder is best understood within the framework of the T-helper lymphocyte (TH) 
cytokine patterns [12].  
 
The dominant mechanism and cell pattern in atopy is skewed towards the T-helper 2 
(Th-2). Th-2 features promote the production of IgE via the secretion of Interleukins 4, 
5 and 13 (IL-4, IL-5 and IL-13) [12, 13]. When IgE on the surface of the mucosal 
mast cells bind to the allergen, degranulation occurs, leading to a release of a host of 
pro-inflammatory mediators, thus causing mucosal inflammation and the physical 
manifestation of the disease. 
 
The role of IgE in the development of allergic disorders and asthma have been 
demonstrated widely [14, 15]. High levels of total serum IgE have been deemed 
reliable enough as an indication of clinical expressions of allergy and asthma [15].  
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 2.2 Dynamics of Th-1 and Th-2 in asthma and allergy 
 
The Th-1/Th-2 paradigm has dominated our understanding of the pathophysiology of 
asthma and allergic disease since the 1980’s [16]. The dynamics of relationship 
between the T-helper 1 and Th-2 process are regulated by numerous environmental 
conditions [17]. The two subtypes of T helper cells were based on cytokine profiles 
defined by Mosman and Coffman [18]. Over the years, it has been proposed that an 
imbalance in the Th-1/Th-2 immune response profile creates the immunological basis 
of allergy and asthma. This concept was first described in murine models, where 
immune response to allergens delivered to the respiratory mucosa were characterized 
by a cross-regulation between Th-1 and Th-2 cell populations [13, 19]. 
 
Th-1 and Th-2 are not the only cytokine patterns possible, T-cells expressing 
cytokines of both patterns also exist and are known as Th-0. These Th-0 cells usually 
mediate intermediate effects depending on the ratio of lymphokines produced and the 
nature of the responding cells [20]. There are also another group of cells known as the 
Th-3 cells, and these cells are capable of producing high amounts of transforming 
growth factor (TGF)-β [20]. 
 
Cross-regulatory activity can also been seen between the Th-1 and Th-2 cell types, in 
particular IFNγ and IL-4 respectively [20]. These two cytokines often oppose one 
another’s actions. There is considerable evidence that IL-4 prevents the priming of 
naïve Th cells to become INFγ producers [20]. However in the presence of IL-12, the 
activity of IL-4 is markedly diminished. Thus, IL-12 is seen not only as an inhibitor to 
the activity of IL-4 (inhibits the differentiation of T cells into IL-4 secreting cells), but 
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 also the enhancer of naïve Th-cell priming for IFNγ producers (IFNγ plays a negative 
regulatory role in the development of Th-2 cells) [20]. Although sharing many 
similarities with IL-4, IL-13 apparently is unable to exhibit direct cross-regulatory 
activity on Th-1 cells [20]. 
 
Various studies have been performed, resulting in a rather considerable amount of 
evidence showing that Th-2 cells indeed have roles as the major players in human 
atopic allergic diseases and asthma [7, 17, 21]. This “Th-2 hypothesis” of allergy 
stated that atopic patients were predisposed with a predominant Th-2 response and a 
decreased Th-1 response [22]. Th-1 cells are involved in cell-mediated inflammatory 
reactions, and they tend to induce delayed type hypersensitivity (DTH) reactions, with 
the production of interferon gamma (IFNγ) at the site of inflammation [23]. This 
mode is different from that of Th-2 reactions, where the cytokines produced 
encourage antibody production, in particular that of IgE, and thus, are mainly found in 
association with strong antibody and allergic response [23]. The mode of which is via 
the production and secretion of an array of cytokines such as IL-4, -5, -9, -10, -13 and 
-25.  
 
Genetically, these cytokines serve to both directly and indirectly activate 
inflammatory and residential effector pathways [24]. The evidence for Th-2 cell 
involvement in atopic allergic disease came about when tests of mRNA expression 
from atopic asthmatic subject’s broncho-alveloar lavage cells showed a predominant 
Th-2 pattern [25]. Other evidences were allergen specific Th-2 type clones were 
isolated from the respiratory mucosa of atopic subjects, lesional skin in atopic 
dermatitis and Th-2 cytokine mRNA profile demonstrated in skin biopsies [26].  
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 The Th-1 and Th-2 patterns of cytokine production were demonstrated first in mouse 
CD4+ T-cell clones [18, 27], followed by human T cells [28]. Th-1 cells are involved 
in cell-mediated inflammatory reactions, whereas the cells of the Th-2 lineage are 
involved in antibody production, particularly IgE responses. Thus, these cells are 
commonly found in association with strong antibody and allergic responses, and 
imbalances in these two were hypothesized to bring about predisposition to allergic 
diseases.  
 
Over the past 5 years, increasing interest has been focused on regulatory T cells that 
have been thought to play a critical role in controlling the expression of asthma and 
allergy [16]. The definition of regulatory T cells are cells that actively control or 
suppress the function of other cells in a generally inhibitory fashion [16]. Although 
the specific workings and mechanisms of these regulatory T cells are not fully 
understood, it is thought that some form of regulatory T cells are able to control the 
development of allergic disease and asthma [16]. The supporting evidence proposed is 
those studies have shown that T cells engineered to secrete TGF-beta, in contrast to 
IFN-gamma secreting Th-1 cells could very effectively reduce airway inflammation 
and AHR [16]. In addition, inflammation in asthma could be inhibited by TGF-beta 
secreting cells as well as by IL-10 secreting cells [16]. From these observations, it is 
thought that other than Th-1 cells, there are other cells, in particular the T regulatory 
cells, that will play an important role in regulating asthma [16]. 
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 2.3 Chromosome 5 
 
The importance of chromosome 5 lies in the fact that the 5q31-33 region contains 
several candidate genes which have been implicated in regulation of IgE and the 
development or progression of inflammation associated with allergy and asthma [29]. 
Candidate genes such as a cluster of cytokine genes (interleukins 3, 4, 5, 9, 13 and the 
β-chain of the IL-12 gene), CD14 gene and genes coding for the corticosteroid 
receptor and the granulocyte macrophage colony stimulating factor are found along 
this section of the chromosome [29]. Linkage and association of polymorphic markers 
in these area to atopy and asthma associated phenotypes have been reported by 




 Figure 2.1: Schematic diagram of chromosome 5q. Blown up section of 5q 31.1-34 





 The initial reports for linkage to chromosome 5q were identified using a candidate 
gene approach [29]. Linkage to 5q has been observed in several populations for 
different phenotypes ranging for asthma and BHR to total serum IgE levels [29]. 
Linkage of 5q has been reported for regulation of total serum IgE levels in the inbred 
and genetically isolated Amish population [29, 30] Two previous genome-wide 
screens have been reported from Oxford and a collaborative group in the US [30]. 
Data from the US study suggested that different ethnic groups harbored different 
susceptibility loci for asthma and atopy [30]. In view of this finding, prior study 
(unpublished data) was carried out to evaluate the linkage of asthma and atopy to the 
chromosomal locus 5q 31-33 in our local population [30]. Linkage analysis performed 
by our previous group and results demonstrated highly significant linkage of asthma 
and atopy phenotypes with the 3 markers D5S2110, D5S2011 and D5S412, with LOD 
scores ranging between 3.8 to 6.8 [30]. These findings have provided the evidence 
that the region on chromosome 5q contains susceptibility genes for asthma and atopy 
in our population and hence our focus on this region and these candidate genes. 
 
2.4 Single Nucleotide Polymorphism (SNP) 
 
Genes are demonstrated in various forms known as alleles and this allows for genetic 
variation between species to occur, giving rise to different phenotypic expressions. 
Single nucleotide polymorphisms (SNPs) are the most abundant form these naturally 
occurring human genetic variations [31], having a frequency of 1% or more within a 
population. And any allele with a frequency < 0.01 is known as a variant [32]. The 
SNP can act both as a physical landmark as well as a genetic marker to determine 
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 transmission of a particular region of the DNA from parent to child [33], this relegates 
it as a useful source for the search and study for complex genetic traits [31].  
 
Polymorphisms are becoming an increasingly straightforward and practical way to 
look at genetic phenomena. There are various different types of variations, such as 
morphological, chromosomal, immunological and protein polymorphisms and the one 
that is most relevant to the study would be genetics and the resulting protein 
polymorphisms. 
 
In recent years, technologies for detecting SNPs have undergone rapid development. 
Association studies have been employed in an attempt to identify genetic 
determinants of complex disease [34]. These association studies rely on the detection 
of polymorphisms in candidate genes and the demonstration that particular alleles are 
associated with one or more phenotypic traits [34].  
 
2.5 Function and role of Cluster of Differentiation 14 (CD14) 
 
Lipopolysaccharide (LPS) is the component found in the cell wall of gram negative 
bacteria, and this endotoxin is a commonly encountered air contaminant in 
environmental settings. The importance of this inhaled endotoxin stems from the fact 
that association of LPS and airway neutrophilic (PMN) inflammation in a higher 
percentage of asthmatics as compared to control subjects [35]. 
CD14 plays an important role in innate immunity by acting as the receptor for LPS. 
Recognition is based on a pattern-recognition receptor and binding occurs with both 
LPS and other bacterial components [36]. The single gene lies close to the genomic 
 12
 region encoding for several cytokines and control of IgE levels [37] and consists of a 
stretch spanning 1.5kb on chromosome 5q31 and has a short intron separating it [38]. 
This membrane bound 53kDa surface glycoprotein [39] is constitutively expressed on 
the surface of monocytes and macrophages [35, 40] and the serum soluble sCD14 can 
be found in human airway fluids [35]. Interest in the role of LPS and asthma stemmed 
from studies demonstrating that inhalation of LPS gave rise to bronchial hyper-
responsiveness [41]. However, LPS alone is insufficient to induce activation of 
bronchoalveloar macrophage cytokines [42].  
 
Studies have shown that a polymorphism in the promoter region of the CD14 gene 
affects the total serum IgE and soluble serum CD14 levels in vivo [36, 40]. The 
polymorphism demonstrated in these two studies showed a C – to – T transition at 
base pair -159 from the major transcription start site (CD14/-159) [40]. They 
hypothesized that the genetic variant had an influencing ability on the Th-cell 
differentiation and hence total serum IgE levels as well [40]. 
 
Interestingly, interactions between bacterial components and CD14 results in a strong 
IL-12 response by antigen presenting cells [40, 43]. IL-12 on its own has also been 
said to have an impact on asthma and allergy via negatively affecting the Th-2 
response. It has been demonstrated that IL-12 plays an important role in the regulation 
of immune responses in the allergic asthma model [44]. 
 
 13
 2.6 Function and role of Interleukin-12 (IL-12). 
 
IL-12 was first discovered independently by investigators at Hoffmann-La Roche, Inc. 
and by Trinchieri and colleagues at the Wistar Institute in collaboration with 
investigators at Genetics Institute [45] and has been established to be a p70 
heterodimeric molecule composed of the p35 and p45 subunit which are linked by a 
disulfide bond [46]. The IL-12 receptor is composed of two distinctive β1 and β2 
subunits which form together to produce the high affinity IL-12 receptor complex (IL-
12R) found on T and NK cells [47]. It is deemed a critical determinant of the Th-1 
mediated immune response, and in the event that the production of the cytokine is 
deficient, a Th-2 polarized immunity would result [48]. The subunits are products of 2 
separate genes: the heavy-chain p40 subunit and the light-weight p35 chain [48]. The 
expression of the p40 chain is tightly regulated whereas the light weight chain p35 is 
constitutively expressed [48]. Again, this gene is found interestingly close to the 
region on chromosome 5q, where other genes relating to asthma and atopy reside. 
 
Biologically active IL-12 is produced by activated macrophages, monocytes, dendritic 
cell and other antigen presenting cells [48]. IL-12 has shown itself to be important in 
influencing the differentiation of naïve CD4+ T cells towards and interferon gamma 
(INFγ) producing Th-1 cell type [46]. IL-12 is a potent augmenter of INFγ and both 
cytokines are essential in the induction of a protective Th-1 immune response to 
intracellular pathogens, with INFγ down regulating the production of IgE [46, 47]. 
The Th-1 inducing effect of IL-12 was contemporarily and independently 
demonstrated in both mice and man [20]. 
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 Studies have also shown that IL-12 has the ability to redirect Th-2 response towards 
the Th-1 immune response both in in vitro and in vivo studies [46]. This lends 
credibility to the fact that numerous studies have shown the importance of IL-12 in 
the prevention of Th-2 immune responses in murine in vivo models of allergic 
diseases [46, 49], and adds evidence that endogenous production of IL-12 is 
protective against the development of airway allergic diseases [49]. Studies in human 
models were demonstrated by Naseer et al [50] which showed that the number of IL-
12 (p40) expressing cells in bronchial biopsy specimens from allergic asthmatic 
patients is significantly less than that found in the lungs of normal controls subjects 
[50]. 
 
2.7 Function and Role of Interleukin 13 (IL-13). 
 
The human interleukin-13 gene (IL-13) exists as a single copy in the haploid genome, 
and it maps to chromosome 5 [51]. Interleukin 13 levels have been found to be 
elevated in the lungs of asthmatic patients, irregardless of their atopic status [52, 53]. 
It has also been shown that IL-13 is a major factor in allergic asthma [4] and that it 
operates through mechanisms separate from those classically implicated in responses 
to allergy [54]. There have been repeated studies demonstrating that atopy was 
coupled to a rise in IL-4, IL-5 and IL-13 levels [13, 55, 56]. 
 
Human cytokines IL-4 and IL-13 are produced by the T-helper type 2 cells when an 
antigen and antigen receptor is engaged [57]. IL-13 is a 114 amino acid cytokine that 
is secreted mainly as an unglycosylated protein with a Mr of 10 000 by activated T-
cells [51, 58], and is produced by activated Th-0, Th1-like cells, Th2-like cells and 
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 CD8-positive T cells [59]. Immunoregulatory functions of IL-13 occur when there is 
interaction between the IL-13 and the B-cells, monocytes and macrophages. 
 
Both IL-13 and IL-4 are able to achieve parallel responses which are associated with 
phenotype of asthma and atopy [57]. IL-13 and IL-4 have been found to share a 
signaling receptor, which is found on a number of normal human cells [57, 60, 61].  
 
IL-13 has been shown to be produced at elevated levels in the asthmatic lung and 
have been postulated to be hallmark features of the disease. IL-13 belongs to the α-
helix super-family and is found on the chromosome 5q31 [62]. It has been 
demonstrated that IL-13 and IL-4 share many functional properties, one of which is 
the common α-subunit of the IL4 receptor.  
 
Although produced by the activated Th2 cells, IL-13 does not appear to be important 
in the initial differentiation of CD4-T-cells into Th2 type cells, but it does appear to 
be important in the effector phase of allergic inflammation [63]. The cDNA for 
human IL-13 has been cloned [63], and shown to have a single open-reading frame 
with 132 amino acids, including a 20 amino acid signal sequence that was cleaved 
from the matured secreted protein [64]. The gene encoding IL-13 consists of 4 exons 
and 3 introns, and is located 12 kb upstream of the gene encoding IL-4 on the 
chromosome 5q31 and both are in the same orientation [65].  
 
IL-13 is a type I cytokine and signals thru the type I cytokine receptors. A type I 
cytokine receptor comprises of 4 conserved cysteine residues, a W-S-X-W-S motif, 
fibronectin type II modules in the extracellular domain which are important  for the 
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 binding of  Janus tyrosine kinases (JAK) [66]. The receptors exhibit constitutively 
associated JAKs, and results in recruitment of downstream signaling molecules [66]. 
The IL-13 receptor comprises of the IL-4Rα and two IL-13 binding proteins, IL-
13Rα1 and IL-13Rα2. It uses the JAK-signal transducer and activator of transcription 
(STAT) pathway and specifically STAT6. The IL-4Rα is a 140-kd protein, consisting 
of an open reading frame of 825 amino acids, including a 25-amino-acid signal 
sequence [63, 67] 
 
Consequences of IL-13 overproduction include symptoms such as airway hyper 
responsiveness, eosinophilic inflammation, IgE production, mucus hyper secretion 
and sub epithelial fibrosis [48]. 
 
An SNP in the coding region of the IL-13 gene, results in an amino acid substitution 
of an arginine with a glutamine at position 130. The 2044 SNP has been shown to be 
associated with asthma, increased IgE levels, atopic dermatitis [1, 9, 68-70].  
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 2.8 Table of Polymorphisms. 
 
Table 2.1: List of Polymorphisms studied.  







CD14 Promoter -159 - C Æ T 
E. Am. J. Respir. Cell 
Mol. Biol. 
20:976 – 983 [40] 
IL-12 3’ UTR 1188 - A Æ C Genes and Immunity 
2000 1:219-224 [71] 
IL-13 Promoter -1512 50012, A704C A Æ C 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
IL-13 Promoter -1112 
-1055, -1111, 
C1103T 
C Æ  T 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
IL-13 Intron 3 +1923 46578 C Æ T 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 




G Æ A 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
IL-13 3’ UTR 4738 +2525 G Æ A 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
IL-13 3’UTR 4793 +2580 C Æ A 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
IL-13 3’UTR 4962 +2749 C Æ T 
J. Allergy Clin. Immunol. 
2000 Mar; 
105 (3):506 – 513 [1] 
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 2.9 Function and role of Immunoglobulin E (IgE). 
 
Immunoglobulin E (IgE) has been hailed as the major player in the pathogenesis of 
allergic diseases and asthma. High levels of total serum IgE have been reported to 
correlate with the clinical manifestations of allergy and asthma [15, 72].  World-wide, 
high total serum levels of IgE have been used as a predictor of the development of 
asthma [15], thus gaining the understanding of the genetic mechanisms governing the 
regulation of total serum IgE levels is critical in dissecting the hereditary components 
of the complex genetic disorder of asthma and atopy. 
 
IgE was first discovered in the middle of the 1960s independently by two groups, 
Ishizaka, Ishizaka & Hornbrook and Johansson & Bennich [73]. These reagenic 
antibodies belonged to a then unclassified immunoglobulin class, later renamed IgE. 
Elevated serum IgE concentrations were reported in asthmatics by Johansson [74], 
and subsequently, it was desired that IgE determinations would make it possible to 
discriminate between atopic and non-atopic individuals [75]. 
 
2.10 Skin Prick Test. 
 
The main method for establishing the presence of allergen-specific IgE antibodies to 
aid in the diagnosis and identification of allergy diseases and its corresponding 
allergen is the skin-prick test (SPT). IgE is known to have a major role in the 
pathogenesis of allergic diseases, based mainly on its ability to bind to specific 
receptor on the mast cell, in order to promote the release of mediators that can 
generate inflammation [76, 77]. However, in order to measure the IgE level, it is 
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 necessary to obtain a serum blood sample. This poses a problem to most individuals, 
who are not open to the procedure. Thus, a less invasive method that could also 
determine the individuals’ response to the allergen would be the skin prick test (SPT). 
The procedure allows the allergen in question to be introduced to the individual via 
surface skin interaction. However, there are disadvantages to this method in assessing 
the severity of atopy. This is simply due to the fact that the response to various 
allergens are subjective to insufficient standardization of dose concentration of the 
allergen used in the test, the environmental factors governing the test  as well as the 
actions of environmental – genetic factors [78].  An intracutaneous prick is applied 
through a drop of allergen on the surface of the skin, resulting in a characteristic 
“wheal and erythema” response is elicited in sensitive individuals. This process is 
highly sensitive for identifying the allergen in question. The benefit of this procedure 
is that it is cheap and provides almost immediate results which are demonstrable to 
the patient. There are however downsides to SPTs. Use of certain medications, in 




 2.11 Reason and aims of doing this study. 
 
Owing to preceding studies demonstrating that the region 5q31-33 on chromosome 5 
houses genes able to influence the pathogenesis of asthma and atopy, we hypothesized 
that these genes were also able to influence the atopy state in our local Chinese 
population here in Singapore.  
 
Fine mapping of the region of interest turned up the two cytokines IL-12 and IL-13, 
and therefore the basis of our study stems from delineating the roles that these two 
cytokines had in atopy in our Singapore Chinese families. Postulation was raised that 
polymorphisms found within the regions of the promoter, coding and non coding 
regions could confer susceptibility to the atopy/allergic phenotypes in our local 
population. 
 
For a better quality of life, it is essential that asthma and atopy be diagnosed early in 
life. This study hopes to provide a better insight into the susceptibility genes for atopy 
and allergy to allow for better understanding and thereby prevention and treatment of 
the disease. 
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 3 Materials and Methods 
 
3.1 Patient Selection 
 
Informed consent was obtained from genetically unrelated patients and volunteers of 
the study trial. Age range of the patients was mainly in late teens to adults (18-50 
years). Normal controls were volunteers with no history of asthma, atopy or allergic 
diseases. Patient or affected individuals were selected based on doctor diagnosed 
atopic disease, and confirmed with laboratory analysis of atopy via a positive reaction 
to dust mite allergen skin prick test. 
 
Subjects were considered atopic if the individual had one or more of the following: 
total serum IgE more than 2 SD above the mean for that age [72-75]; and a positive 
skin prick test (> 3mm greater than negative control) or positive specific IgE by 
fluorescent allergosorbent test (FAST) (> class 2 or > 0.75 IU/ml) to an important 
dust mite in the tropics, Dermatophagoides pteronyssinus (Dp). Total serum IgE and 
Dp specific IgE were measured by FAST (Biowhittaker, Maryland, USA).  
 
Table 3.1 lists out the averages for total IgE levels, male female ratios as well as the 
various information of the sample population. 
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 Table 3.1: Table demonstrating average total IgE levels, male-female ratio and 





MALE : FEMALE 69 F : 45 M 37 F : 43 M 







DERMATITIS 109 14 
ASTHMA 109 21 
Note: 
Average TTIgE – Average Total IgE 
The value stated under the negative controls reflects the number of individuals used to 
compare against the affected individuals. By no means, does it indicate that they are 
affected by the condition (e.g. 106 rhinitis does not mean 106 negative controls who 
have rhinitis. Rather, it indicates that 106 negative controls were compared to 28 
affected individuals for the phenotype of rhinitis). 
 
3.2 Allergen Specific IgE Evaluation via Skin Prick Test 
 
Skin prick test (SPT) is one of the most common methods of allergy testing. The test 
involved placing a small drop (5μl) of a suspected allergen (D. pteronyssinus, Greer 
Laboratories, North Carolina, USA) on the surface of the skin. The area tested is 
usually the forearm and the upper arm. The skin is then scratched or pricked with a 
sterile disposable lancet to allow the allergen to be introduced under the surface of the 
skin. The skin is then observed closely for signs of reaction, such as swelling and 
redness of the site of prick. Results are obtained within 20 minutes of initial prick (Fig 
3.1-3.2). 
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 Figure 3.1: Lancet used for skin prick test 
 
Figure 3.2: Results of skin prick test. 
 
 
3.3 FAST and Pharmacia Immunocaps 
 
The samples total serum IgE levels were measured both by fluorescent allergosorbent 
test (FAST) (Biowhittaker, Maryland, USA) and ImmunoCAP (Pharmacia) system. 
The assay threshold was set at 122.00 U/mL (+ 2SD), as described by the PRIST 
Technique (paper radioimmunosorbent test kit, Pharmacia Diagnostic, Piscatawa, NJ). 
Both methods are generally used in laboratories as a measure of serum IgE levels. 
Due to the manufacturing shut down of FAST by Biowhittaker, measurement of 
serum IgE was conducted via ImmunoCAP.  
 
The crux of the innovative ImmunoCAP technology is a cellulose polymer in a plastic 
reserve. This unique technology bestows a high binding capacity of clinically relevant 
allergen proteins, including those present in very low levels. This provides increased 
sensitivity, specificity, and reproducibility in the results. The principle of the assay is 
employment of the fluorescent enzyme immunoassay, in which a reading of more 
than 0.35kIU/l of specific IgE was considered as a specific sensitization.  
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 3.4 Phenol Chloroform Extraction for DNA 
 
Extraction of white blood cells (WBC) from whole blood. 
 
5 to 10mls of whole blood was collected in an EDTA tube (Ethylenediamineteraacetic 
Acid Disodium Salt). All consumables used were RNAse and DNAse free. Chilled 
solutions were used to slow down the action of the DNAse’s.  The cells were 
transferred to a plain 10ml Stardest ® tube, resuspended and first washed with cold 
TE10/10 (Tris-EDTA 10 mM / 10 mM). The washed intact nuclei left were pelleted 
by centrifugation at 6000rpm for 10 minutes at 4 degree Celsius and the supernatant 
decanted. The washing step was repeated till all traces of haemoglobin were removed.  
 
Following the last wash, the pellet was resuspended in 1ml of TE10/10 and lysed with 
30μl Proteinase K (30mg/ml) and 160μl of 10% SDS. Tris buffer was used to 
maintain the pH near physiological levels (pH 6.0 – 8.0). Too acidic or alkaline and 
environment would result in either hydrolysis or denaturation of the DNA 
respectively. The biological detergent SDS dissolved lipids in the nuclear membrane, 
allowing the DNA to be released and purified by Proteinase K. The tube was then 
incubated overnight in a 37oC water bath. 
 
After being removed from the water bath, the tubes were given a quick spin to 
consolidate the DNA at the bottom of the tube. Due to the involvement of organic 
solvents, the following steps were carried out in the fume hood. 
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 An equal amount (1:1 ratio) of 8-hydroxyquinoline equilibrated room temperature 
phenol was added to the samples. Equilibration was done to prevent oxidative damage 
to DNA. Tubes were tightly capped before being rotated for 7 minutes to allow 
homogeneous mixing between sample and phenol.  
 
Centrifugation at 3000rpm for 10 minutes would separate the samples into three 
phases, phenol at the bottom; proteins in the interphase and genetic material in the 
upper phase. Care was taken to ensure that the upper phase was not agitated or 
disturbed while the lower and interphases were being removed via pipetting. 
Chloroform/isoamyl alcohol (24:1) was added in equal amounts (1:1 ratio) to the 
upper phase in the same tube. The tube and its contents were then again mixed and 
rotated for 7 minutes to allow homogenous mixing of the genetic material and the 
chloroform/isoamyl alcohol mixture. The contents were then centrifuged for 10 
minutes at 3000rpm. As before, the contents were separated into three phases: The 
lower phase containing the chloroform/isoamyl alcohol mixture, the interphase 
containing the protein debris and other impurities and the upper phase containing the 
genetic material.  
 
As before, care was taken to ensure that the upper phase was not disturbed while the 
lower and interphases were removed via pipetting. However, if a thick interphase was 
present, the upper phase would be transferred to a fresh tube. 
 
DNA from the upper phase was precipitated using 1ml of solution, 63μl of 4M 
Sodium chloride (NaCl) and 2 volumes of ice cold 100% ethanol. Caution was taken 
to avoid vortexing and harsh treatment to the solution to prevent breakage and 
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 shearing of the DNA. Once the DNA strands were precipitated, the solution was 
carefully aspirated out, leaving the DNA inside the tube. Residual salt from the pellet 
was removed by washing with 2mls of ice cold 70% ethanol. The tube was placed on 
the rotator and allowed to mix well for 7 minutes. The contents were given a quick 
spin to pellet the DNA and prevent it from being decanted together with the 70% 
ethanol. 2mls of ice cold 100% ethanol was added to the pellet and mixed to remove 
traces of 70% ethanol. The pellet was centrifuged once again and the 100% ethanol 
decanted. Air dried DNA pellet was resuspended with DNase/RNase free water. The 
pellet was then incubated overnight at 37oC. To determine the concentration of DNA 
obtained, 5μl of DNA was mixed with 45μl of distilled water (1:10 dilution) and read 
at A260 on the spectrophotometer. DNA concentration in μg/ml was calculated with 
the following formula: 
 
A260 x dilution factor (10) x 50  = DNA concentration in μg/ml 
  1000 
 
Where; 
A260 = Absorbance at wavelength 260nm (also known as OD – Optical Density). 
A260 reading of 1.0 will yield approximately 50 µg of dsDNA or approximately 37 
µg of ssDNA. 
The purity of the DNA obtained is measured by the formula: 
A260 / A280 = 1.8 for pure DNA. 




 Figure 3.3: Precipitated DNA from solution. 
 
 
3.5 Polymerase Chain Reaction (PCR) 
 
The Polymerase Chain Reaction (PCR) is a major development in the analysis of 
DNA. This technique is used for the in vitro amplification of specific DNA sequence 
by simultaneous primer extension of complementary strands of DNA. PCR has both 
simplified existing technology and enabled the rapid development of new techniques 
which would not otherwise have been possible. The primer extension reaction 
employs the DNA polymerase to carry out the synthesis of a complementary strand of 
DNA in the 5' to 3' direction using a single-stranded template, but starting from a 
double-stranded region, and is the basis for a variety of labeling and sequencing 
techniques. 
 
3.6 Restriction Fragment Length Polymorphism (RFLP)  
 
Although RFLP has been hailed as one of the easiest and most direct method of 
analyzing SNP in the DNA, it however has its advantages and disadvantages. 
Restriction enzymes are capable of recognizing specific oligonucleotide sequences 
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 and orchestrate double stranded breaks near or within the sites of recognition. If the 
site of interest does not have a specific recognition site, a site-directed PCR mutation 
is carried out to produce a recognitions site. This is done by changing a base pair on 
the primer to create a site directed mismatch.  
 
The first few rounds of the PCR would yield slight changes into the newly 
synthesized strands of DNA. However with following cycles, the DNA that is primed 
with the primers would yield DNA strands with the newly inserted base pairs, creating 
a pool of DNA that, if done carefully and optimized to perfection, would yield a DNA 
pool that consisted of DNA with the newly introduced base pair, and thus achieving a 
recognition site for the restriction enzyme to recognize and cleave to produce the 
fragments of identification. The method is however not without its faults.  
 
An optimized reaction presents as a single clear band, without faint non-specific 
bands or primer dimers. Purification by GFX column would allow for a clearer and 
better digestion. 
 
There are two classes of restriction enzymes, the type II category being the more 
popular of the two [79]. The type II restriction enzymes are the ones that hold the 
main key to the manipulation of genetics. Upon recognition, the double stranded DNA 
at positions close to or within the regions are nicked to produce unique restriction 
fragments.   
 
Agarose has the property of cross-linking large polysaccharide molecules. Application 
of a difference in voltage across the gel makes it possible to impel fragments of 
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 negatively charged DNA molecules to move through the agarose, away from the 
cathode and towards the positively charged anode. Because of the cross-linking in the 
agarose, larger molecules have a greater resistance to overcome while moving through 
the gel than the small fragments, thus they travel slower through the gel. The distance 
the DNA has moved is measured from the well it was loaded in to (at the cathode end), 
to the centre of the band at the end of the run. This distance traveled has a rough 
logarithmic relationship with the molecular weight of the DNA.  
 
It is essential to separate out the bands as much as possible without losing any or 
allowing any of the fragments merge. This is achieved by different percentage gels – 
different percentage results in different pore size created during the cross linkage of 
the agarose – and electrophoresing it at different current strengths. This would not 
only aid in giving different specific resistance to the samples traveling through the gel, 
but would also help to clarify each band and obtain accurate and measurable results. 
 
During loading, the DNA is pipetted in to their individual wells, together with a 
running of loading dye which also runs towards the anode. The dye has a higher 
molecular weight than the DNA, and thus would move faster than the DNA. This 
property of the dye would ensure that the smaller fragments of the DNA do not run 
out of the gel, as it acts as a marker to terminate the run. During loading of the sample, 
it is essential that the DNA concentration is not too high, as it may affect and retard 
the movement through the gel, high concentration of salts in the buffer would also 
cause retardation of the run. 
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 Once the run is complete, it is important to visualize the positions of the bands of the 
genetic material. Ethidium bromide was previously added into the molten agarose to 
minimize having to soak in a bath of ethidium bromide. Ethidium bromide has both 
the properties of fluorescing under ultra violet light and of getting between the bases 
on a DNA molecule. The DNA in the gel will allow incorporation of the ethidium 
bromide and will appear as fluorescent bands on the gel. This will determine their 
positions when exposed to UV light.  
 
The band positions are recorded and used to determine the size of each fragment. 
Ethidium bromide can get between the bases of DNA and is therefore a potential 
mutagen and carcinogen. Exposure to it should be kept as low as possible. The 
mobility’s of DNA fragments of a determined size are plotted against the log10 of 
their size. By this method the size of unknown fragments can be determined by 
reading the distance they have moved against the equivalent log size on the graph. 
 
The DNA molecule is negatively charged, therefore when loading the gel, the wells of 
the gel are placed at the negative end of the tank and the gel front faces the positive 
end. The smaller the molecule, the faster it runs through the gel. Vice versa, the larger 
the molecule, the slower it runs. Thus at the end of the run, what is seen is that the 
smaller fragments have migrated to the point furthest away from the loading site, 
while the larger fragments are resting nearer to it. 
 
The overall effect of the separation is affected by other conditions such as gel 
thickness, electrophoresis temperature, buffer selection and voltage of run. 
Electrophoresis produces heat, and lower percentage gels tend to be more susceptible 
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 to melting in high temperatures than higher percentage gels. In our case, a 2% gel was 
used routinely, and therefore, this did not pose a problem. However, the higher the 
percentage of gel, the more opaque and auto-fluorescence it becomes, and thus, when 
preparing the gel, it should be kept within 3-4mm thick.  
 
Buffer selection is also an important issue. Our experiments were run on 1x TBE 
buffer. TBE generates less heat, has a high buffering capacity, low conductivity and is 
less subjective to pH drift, and is therefore practical for use in high voltage 
electrophoresis. The temperature at which the gel is subjected to also play a role in the 
bands obtained. Too high a temperature and too fast a speed at which the bands were 
electrophoresis in would lead to gel artifacts and misaligned gel bands.  
 
Problems such as S-shaped migration fronts, lopsided gel bands and uneven migration 
of bands would result from a hasty and inappropriate temperature run. This gives rise 
to difficulty in interpreting the fragment sizes. Prolonged high temperature runs would 
cause the buffer to heat up and in turn cause the gel to melt, thus destroying the entire 
run.  
 
Ethidium bromide has been used for many years as a nucleic acid stain, and under 
ultraviolet light, ethidium bromide fluoresces a reddish-orange color. Ethidium 
bromide is either obtained in powder or solution form and is soluble in water. As the 
powdered form is more dangerous to work with, and poses as an irritant to the upper 
respiratory tract, eyes and skin, the solution form of ethidium bromide was used at a 
concentration of 0.5μg/ml.  
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 Ethidium bromide is strongly mutagenic, causing living cell mutations. Even though 
there is no evidence at this time of human carcinogenicity or teratogenicity, this 
material should be considered a possible carcinogen or teratogen. Ethidium 
intercalates into the DNA and alters the base-stacking interaction in the double helix.  
 
The intercalation causes the helix to extend and unwind. Exposure to short wave UV 
light (595nm) will cause the intercalated DNA to fluoresce bright reddish orange [80]. 
To minimize excessive background staining, the agarose gel is de-stained by soaking 
in de-ionized water for 10 minutes. 
 
3.7 Sequencing for polymorphisms. 
 
Chain termination sequencing was employed. This method involves the synthesis of 
new strands of DNA which act as a template for the enzymatic synthesis of new DNA 
starting at a defined primer site. All four deoxyribonucleotide triphosphates (dATP, 
dGTP, dCTP, dTTP) including the four dideoxynucleotides are externally supplied for 
the extension of the DNA strand. The dNTP’s are labeled with a different color 
fluorescent tag. The dideoxynucleotide concentrations are carefully adjusted so that 
they are incorporated into a single strand.  
 
Elongation proceeds until a dideoxynucleotide is inserted. The dideoxynucleotide 
lacks a 3’-OH group on the ribose ring and thus presence of a dideoxynucleotide at 
the 3’end of a growing DNA strand blocks further incorporation of nucleotides. This 
is the key principle to the dideoxy DNA sequencing method.  
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 The fragments are then separated based on size. As each labeled DNA fragment 
passes thru the capillary in the ABI PRISM 3100 sequence detector (Perkin-Elmer). 
The color is detected by the laser and is recorded. The sequence is then reconstructed 
from the pattern of colors detected and produced as a sequencing chromatogram. The 
base pairs would be seen as clear concise peaks with little or no background noise. 
However, in the event that a heterozygous base pair is encountered, the computer 
would record the higher of the two peaks, or if the two heterozygous peaks are 
roughly of the same height, the resulting base pair would be recorded as “N”.  
 
The base-calling generated by the ABI sequencer were blasted with the sequences 
obtained from the National Centre for Bioinformatics (NCBI). This process served to 




 3.8 Sample population and experimental protocols used in our study 
 
Genomic DNA from 109 unrelated volunteer controls (non-atopic, non-asthmatic, 
total IgE < 122.00 U/mL) and 77 unrelated affected volunteers (high total IgE; > 
122.00 U/mL, atopic – defined by having at least one positive skin prick test to an 
allergen or positive specific IgE to an allergen) unrelated Chinese Singaporeans were 
screened for the CD14 -159 C/T, IL-12 1188 A/C, and 7 IL-13 genetic 
polymorphisms reported.  
 
3.8.1 CD14 -159C/T Polymorphism. 
 
The PCR for CD14 -159 C/T was modified from the protocol used by Baldini et al 
[38]. PCR for SNP -159 C/T was carried out in a 25μl volume consisting of 20ng 
DNA, 0.48μM of each primer, 50mM KCl, 10mM Tris-HCl, 0.2mM of each dNTP, 
1.5mM MgCl2 and 1 U of Taq DNA polymerase (Roche). Cycling conditions were as 
follows: 95oC for 3 min; 30 cycles at 95oC for 30 s; 58oC for 30s, 72oC for 45s; with a 
final extension step of 72oC for 10 min. The primers used are described in Table 3.2. 
All PCRs were carried out on the PTC-100TM Programmable Thermal Controller, MJ 
Research, INC. 
 
Table 3.2: Primers used for CD14 -159 C/T PCR amplification and size of amplified 
product 
Polymorphism Primers Annealing Size 
-159 C/T 5’– GTGCCAACAGATGAGGTTCAC –3’ 
5’– GCCTCTGACAGTTTATGTAATC –3’ 
58oC 497 bp 
* GenBank accession number AFO97335 was used as the reference sequence. 
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 The conditions of the RFLP are detailed in Table 3.3. The procedure was subjected to 
an overnight (16hours) digestion. The 497bp PCR and RFLP products were run on 
2% agarose gel (Seakeam ® LE agarose) at 150Volts, using a 50bp marker from 
GeneRulerTM 50bp DNA Ladder Plus (MBI Fermentas). A stock volume of 10X 
TBE was prepared using 108g Tris base (J. T. Baker), 55g boric acid (Sigma-
Aldrich), 40ml 0.5M EDTA, pH 8.0 (NUMI) topped up to 1 Liter with de-ionized 
water. Loading buffer was prepared from 0.25% Bromophenol blue (Sigma-Aldrich), 
0.25% xylene cyanol FF(Sigma-Aldrich), 15% Ficoll type 4000 (NUMI), 120mM 
EDTA (Duchefa). 
 
A 2% agarose gel is composed of 2g agarose dissolved in 100ml of 1X TBE. 
Ethidium bromide was added in at a concentration of 0.5μg/ml and swirled to allow 
through mixing.  
 
For gel loading, 3μl of loading dye is mixed well with 15μl of digested DNA sample 
and loaded into the well together with a DNA marker. The gel was then 
electrophoresed at 150 volts, visualized on a long wave UV light box and imaged. 
 
Table 3.3: CD14 -159 C/T polymorphism’s restriction enzyme and temperature 
requirement. 
Polymorphism      Restriction Enzyme          Temperature  
 
     -159 C/T           0.5 U Ava II                 37oC  






 3.8.2 IL-12 Promoter, Exons 6, 7 and Exon 8 1188 A/C Polymorphism. 
 
The PCR for the IL-12 promoter region was amplified in four overlapping regions. 
Each section was amplified in a 25μl volume consisting of 20ng DNA, 0.48μM of 
each primer, 50mM KCl, 10mM Tris-HCl, 0.2mM of each dNTP, 1.5mM MgCl2 and 
1 U of Taq DNA polymerase (Roche). Cycling conditions for the four overlapping 
regions were as follows: 95oC for 5 min; 30 cycles at 95oC for 40s; 58oC for 40s, 72oC 
for 45s; with a final extension step of 72oC for 10 min. Table 3.4 describes the 
primers used for the amplification of the promoter region. The four primers used for 
the IL-12 promoter region are labeled as IL-12 Promoter 1 to IL-12 Promoter 4 
(However note that there is only one promoter region). All PCRs were carried out on 
the PTC-100TM Programmable Thermal Controller, MJ Research, INC. 
 
PCR for IL-12 exons 6 and 7 were carried out in a 25μl volume consisting of 20ng 
DNA, 0.48μM of each primer, 50mM KCl, 10mM Tris-HCl, 0.2mM of each dNTP, 
1.5mM MgCl2 and 1 U of Taq DNA polymerase (Roche). Cycling conditions for the 
two exons were as follows: 95oC for 2 min; 30 cycles at 95oC for 30s; 55oC for 30s, 
72oC for 45s; with a final extension step of 72oC for 10 min. Table 3.4 describes the 
primers used for the amplification of these two exons. All PCRs were carried out on 
the PTC-100TM Programmable Thermal Controller, MJ Research, INC. 
 
PCR for IL-12 exon 8 (SNP 1188 A/C) was carried out in a 25μl volume consisting of 
20ng DNA, 0.48μM of each primer, 50mM KCl, 10mM Tris-HCl, 0.2mM of each 
dNTP, 1.5mM MgCl2 and 1 U of Taq DNA polymerase (Roche). Cycling conditions 
were as follows: 95oC for 2 min; 30 cycles at 95oC for 30s; 50oC for 30s, 72oC for 45s; 
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 with a final extension step of 72oC for 10 min. The primers used are described in 
Table 3.4. All PCRs were carried out on the PTC-100TM Programmable Thermal 
Controller, MJ Research, INC. 
 
Table 3.4: Primers used for IL-12 PCR amplification and size of amplified product 
Polymorphism Primers Annealing Size 
IL-12 Promoter 1 5’ – TCTTTTGCATAACTGGCGCTG – 3’ 
5’ – CTTCCCAGCCGCACACTTC– 3’ 
58oC 643bp 
IL-12 Promoter 2 5’ – GGATGGGAGGAGGCGCTC– 3’ 
5’ – ACACAAATCTATGGCCCTAGG – 3’ 
58oC 643bp 
IL-12 Promoter 3 5’ – TACATGTTCCTGTTCACGTGC – 3’ 
5’ – CAGACGGGAGGCTGAGTTC– 3’ 
58oC 619bp 
IL-12 Promoter 4 5’ – GGACTAATGTGGAGGAAGGC – 3’ 
5’ – TTGGGAAGTGCTTACCTTGC – 3’ 
58oC 572bp 
Exon 6 5’ – GTCCCATCTGATTGTTCAGTG – 3’ 
5’ – GTAGTAGGCTATACCATCTAG – 3’ 
55oC 649bp 
Exon 7 5’ – CAAAGTACAAAAGCTGCACC – 3’ 




5’ – GCATTCTCTTCCAGGTTCTG – 3’ 
5’– CTGATGTGCTTGCAGCCTTG –3’ 
50oC 441bp 
* GenBank accession number AY008847 was used as the reference sequence. 
 
Sequencing was used to search for any novel polymorphisms in the promoter region, 
exons 6 and 7, as well as to confirm SNP 1188 A/C. It was carried out using BigDye 
Terminator Version 3 (Perkin-Elmer) on the ABI PRISM 3100 sequence detector 
(Perkin-Elmer). Primers used were described in Table 3.5. 
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 PCR products were obtained and purified with GFX PCR DNA & Gel Band 
Purification Kit (Amersham Biosciences). Big Dye kit and 3100 DNA Analyzer (ABI) 
were used for sequencing the 10μl volume consisting of 2μl BigDye Terminator 
Version 3 (Perkin-Elmer), 3.2pmol of sequencing primer reaction. Cycling conditions 
was as follows: 96oC for 2 min, 25 cycles at 96oC for 35 sec, 58oC for 20 sec, 60oC 
for 4 min and holding at 4oC on the PTC-100TM Programmable Thermal Controller, 
MJ Research, INC.  
 
Table 3.5: Primers used for sequencing of IL-12 promoter, exons 6 to 8. 
    Polymorphism                                      Primer 
IL-12 Promoter 1  5’ – CTTCCCAGCCGCACACTTC– 3’ 
IL-12 Promoter 2 5’ – ACACAAATCTATGGCCCTAGG – 3’ 
IL-12 Promoter 3 5’ – CAGACGGGAGGCTGAGTTC– 3’ 
IL-12 Promoter 4 5’ – TTGGGAAGTGCTTACCTTGC – 3’ 
Exon 6 5’ – GTAGTAGGCTATACCATCTAG – 3’ 
Exon 7 5’ – CCAGGTGCACCGAGAGTGC – 3’ 
Exon 8 1188 A/C  5’ – CTGATGTGCTTGCAGCCTTG – 3’ 
 
An overnight digestion (16 hours) was carried out on the samples to identify the IL-12 
1188 A/C polymorphism. The conditions and enzyme used for the experiment are 
listed in Table 3.6. Both the PCR and RFLP products were run on 2% agarose gel 
(Seakeam ® LE agarose) at 150Volts, using a 50bp marker from GeneRulerTM 50bp 
DNA Ladder Plus (MBI Fermentas).  
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 A stock volume of 10X TBE was prepared using 108g Tris base (J. T. Baker), 55g 
boric acid (Sigma-Aldrich), 40ml 0.5M EDTA, pH 8.0 (NUMI) topped up to 1 Liter 
with de-ionized water. Loading buffer was prepared from 0.25% Bromophenol blue 
(Sigma-Aldrich), 0.25% xylene cyanol FF(Sigma-Aldrich), 15% Ficoll type 4000 
(NUMI), 120mM EDTA (Duchefa). 
 
A 2% agarose gel is composed of 2g agarose dissolved in 100ml of 1X TBE. 
Ethidium bromide was added in at a concentration of 0.5μg/ml and swirled to allow 
through mixing.  
 
3μl of loading dye was mixed well with 15μl of digested DNA sample and loaded into 
the well together with a DNA marker. The gel was then electrophoresed at 150 volts, 
visualized on a long wave UV light box and imaged. 
 
Table 3.6: IL-12 1188 A/C polymorphism restriction enzyme and temperature 
requirement. 
Polymorphism Primers RE / Temp oC 
1188 A/C 5’ – GTGCCAACAGATGAGGTTCAC – 3’ 
5’ – GCCTCTGACAGTTTATGTAATC – 3’ 




 3.8.3 IL-13 Polymorphisms 
 
The PCR for the IL-13 polymorphisms were modified from the protocol used by 
Graves et al [1]. PCR for all the IL-13 SNP’s were carried out in a 25μl volume 
consisting of 20ng DNA, 0.48μM of each primer, 50mM KCl, 10mM Tris-HCl, 
0.2mM of each dNTP, 1.5mM MgCl2 and 1 U of Taq DNA polymerase (Roche).  
 
Cycling conditions for IL-13 polymorphisms -1512, -1112 and +2044 were as follows: 
94oC for 2 min; 30 cycles at 94oC for 30s; 68oC for 30s, 72oC for 45s; with a final 
extension step of 72oC for 10 min. The primers used as well as their respective 
annealing temperatures are described in Table 3.7.  
 
Cycling condition for IL-13 polymorphism +1923 was as follows: 94oC for 2 min; 30 
cycles at 94oC for 30s; 65oC for 30s, 72oC for 45s; with a final extension step of 72oC 
for 10 min. The primers used as well as the annealing temperature is described in 
Table 3.7.  
 
For the three 3’ UTR polymorphisms, cycling conditions were as follows: 94oC for 2 
min; 30 cycles at 94oC for 30s; 63oC for 30s, 72oC for 45s; with a final extension step 
of 72oC for 10 min. The primers used as well as the annealing temperature is 
described in Table 3.7.  
 




 Table 3.7: Primers used for IL-13 PCR amplifications and size of amplified products. 




-1512 5’ – CAACCGCCGCGCCAGCGCCTTCTC – 3’ 
5’ – CCGCTACTTGGCCGTGTGACCGC – 3’ 
68 246 
-1112 5’ – GGAATCCAGCATGCCTTGTGAGG – 3’ 
5’ – GTCGCCTTTTCCTGCTCTTCCCGC – 3’ 
68 246 
+1923 5’ – GGCTGAATATCCATGGTGTGTGTCC – 3’ 
5’ – GGCTGAGGTCGGCTAGGCTGAAGAC – 3’ 
65 559 
+2044 5’ – CTTCCGTGAGGACTGAATGAGACGGTC – 3’ 




5’ – GAGTGTGTTTGTCACCGTTGGG – 3’ 
5’ – CTCCTCAGAGTCTTCAGACCAC – 3’ 
63 473 
GenBank accession number U31120 was used as the reference sequence. 
Single base pair change in primer is denoted by the bold, underlined letter 
 
The products obtained from the amplification process were subjected to an overnight 
digestion (16 hours) to identify the respective polymorphism. The conditions and 
enzymes used for the experiment are listed in Table 3.8. 
 
3μl of loading dye was mixed well with 15μl of digested DNA sample and loaded into 
the wells together with a 50bp marker from GeneRulerTM DNA Ladder Plus (MBI 
Fermentas). 
  
The gel was then electrophoresed at 150 volts and visualized on a long wave UV light 
box and imaged. 
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 Table 3.8: IL-13 polymorphisms restriction enzymes and temperature requirements. 
Polymorphism                    Restriction Enzyme Temp oC 
-1512 0.5 U BstUI         60oC 
-1112 0.5 U BstUI         60oC 
+1923 0.5 U BsaAI         37oC 
+2044 0.5 U NlaVI         37oC 
 
Sequencing was done to re-confirm the presence of IL-13 SNPs -1512, -1112, +1923 
and +2044, as well as to identify the 3 3’UTR polymorphisms +4738, +4793 and 
+4962. All sequencings were carried out using BigDye Terminator Version 3 (Perkin-
Elmer) using the ABI PRISM 3100 sequence detector (Perkin-Elmer). Primers used 
for the respective polymorphisms are described in Table 3.9. 
 
PCR products were first purified with GFX PCR DNA & Gel Band Purification Kit 
(Amersham Biosciences) and sequenced with the Big Dye kit on the 3100 DNA 
Analyzer (ABI). Sequencing PCR was carried out in a 10μl volume consisting of 2μl 
BigDye Terminator Version 3 (Perkin-Elmer) and 3.2pmol of sequencing primer.  
 
Cycling conditions of the sequencing PCR for polymorphisms IL-13 -1112 and -1512 
were as follows: 96oC for 2 min, 25 cycles at 96oC for 35 sec, 58oC for 20 sec, 60oC 
for 4 min and holding at 4oC on the PTC-100TM Programmable Thermal Controller, 
MJ Research, INC.  
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 Cycling condition for polymorphisms IL-13 +1923 and +2044 were carried out as 
follows: 25 cycles at 96oC for 10 sec, 50oC for 5 sec, 60oC for 4 min and hold at 4oC 
on the GeneAmp® PCR system 9000 PE Applied Biosystems.  
 
For polymorphisms +4738, +4793 and +4962, cycling conditions were as follows: 
96oC for 2 min, 25 cycles at 96oC for 10 sec, 58oC for 5 sec, 60oC for 4 min and 




 Table 3.9: Primers used for sequencing of the various IL-13 polymorphisms.  
Polymorphism Primer 
-1112 5’ – GGAATCCAGCATGCCTTGTGAGG – 3’ 
-1512 5’ – CAACCGCCGCGCCAGCGCCTTCTC – 3 
+1923 5’ – GGCTGAATATCCATGGTGTGTGTCC – 3’ 
+2044 5’ – GGCTGAATATCCATGGTGTGTGTCC – 3’ 
+4738 5’ – CTCCTCAGAGTCTTCAGACCAC – 3’ 
+4793 5’ – CTCCTCAGAGTCTTCAGACCAC – 3’ 
+4962 5’ – CTCCTCAGAGTCTTCAGACCAC – 3’ 
 
3.8.4 Precipitation of sequencing products. 
 
Following sequencing reactions, the products were precipitated using the Sodium 
acetate/ethanol method. A master mix of the following reagents (Table 3.10) was 
prepared and 80 μl of the master mix were added into each sample. The samples were 
vortexed well to mix, and placed on ice and in the dark for no shorter than 20 minutes. 
Following incubation, the samples were centrifuged at maximum speed (13.2 x 1000 
rpm) for 25 minutes. The supernatant was then carefully aspirated out, taking care to 
ensure that the pellet was not disturbed. 200 μl of 75% ethanol was then added to the 
tube and vortexed to mix. The samples were then again centrifuged at maximum 
speed (13.2 x 1000rpm) for 5 minutes. Once again, the supernatant was aspirated out 
carefully, and washed one last time with 100 μl of 75% ethanol. Following the last 
centrifugation step, the pellet was allowed to air dry completely. To speed up the 
drying step, the products were dried at 60oC for 4 minutes.  
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 Sample preparation for sequencing consisted of addition of 12 μl of HiDi Formamide 
(HiDi Formamide, Sample Resuspension Solution, 25, Applied Biosystems) and 
denatured at 95oC for 2 minutes before being placed on ice. The samples were loaded 
into the 96 well plate (Applied Biosystems) and run. Genotype was determined by 
visual inspection of the sequence files.  
 
Table 3.10: Precipitation step for all sequenced products. 
Per sample 
Amount  
62.5 μl 95% Ethanol 
14.5 μl Distilled water 
3.0 μl 3M Sodium acetate pH 4.6 
 
3.9 Statistical Analysis 
 
3.9.1 Allele Frequencies 
 
Allele frequency is defined as the frequency with which alleles of a given gene is 
present in a population [76]. The frequency of co-dominant alleles can be determined 
by simply counting the copies of each allele present in the population. The advantage 
of allelic frequencies over the genotypic frequency is that in sexually reproducing 
organisms, genotypes break down to alleles when gametes are formed, and it is the 
alleles and not the genotypes that are passed from one generation to another. Thus, it 
is the alleles that have continuity over time and the gene pool evolves through 
changes in the frequencies of alleles. 
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 Allele frequencies can be calculated either from the observed numbers of different 
genotypes at a particular locus or from the genotypic frequencies. 
 
The formula for allele frequency is: 
 
Allelic Frequency = Number of copies of a given allele in the population
     Sum of all alleles in the population 
 
3.9.2 Hardy Weinberg Equilibrium 
 
The statement that allele and genotype frequencies remain constant from generation to 
generation when the population meets certain assumptions [76] defines the Hardy 
Weinberg law. The law is based on a mathematical formula that is used to determine 
allele frequencies when one or more alleles are recessive and assumptions are met 
[76]. The assumptions are: 
 
1. The population has to be large, in order to avoid errors in measuring allele 
frequencies. 
2. All genotypes have equal ability to survive and reproduce. There is no one 
genotype better than the other. 
3. Random mating is in order. 
4. Factors that change allele frequency, such as migration, mutation, are either 
absent, or rare events, can be ignored. [76] 
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 The equation for the Hardy Weinberg law is: p2 + 2pq + q2 = 1;  
 
Where p = homozygous dominant gene 
 q = homozygous recessive gene 
 pq = heterozygous gene. 
 
In short, the Hardy-Weinberg law explains what happens to a population’s allelic and 
genotypic frequencies as the alleles are passed from generation to generation in the 
absence of evolutionarily relevant processes. 
 
 48
 3.9.3 Z-Score 
 
Possible associations between the genotypes/haplotypes and the clinical phenotypic 
manifestations were tested using the Z-Score analysis. 
 
Z-score, also known as standard scores, is a special application of the transformation 
rules [81]. The Z-score is an indication of how far, and in what direction the results 
deviate from it’s distribution mean, and it is expressed in units of its distribution 
standard deviation [81]. It is useful when we want to quantify how different a 
recorded value is from the normal value, as well as when combining and/or 
comparing different features or measures. Mathematically, the Z-score is derived from 
the formula:  
 
Z-Score = (value – mean)  
                   Standard Deviation 
 
Z-scores are highly informative when the distribution is normal. In every normal 
distribution, the distance between the mean and a given Z-score cuts off a fixed 
proportion of the total area under the curve, and statisticians have provided tables 
which indicate the values of these proportions foe each possible score [81].  
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 4 Results 
 
4.1 CD14 -159 C/T Polymorphism. 
 
A total number of 109 unrelated controls and 77 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the CD14 -159C/T 
polymorphism. 
 
The restriction enzyme employed is AvaII. The source is from an Escherichia coli 
strain that carried the cloned AvaII gene from Anabaena variabilis (ATCC 27892) 
[82]. The enzyme’s recognition site is 5’ – G’GA(T)CC – 3’ and 3’ – CCT(A)G’G – 
5’. Activity of the enzyme is at 37oC, and inactivation of the enzyme occurs at 65oC 
for 20 minutes. Activities of certain enzymes are also inhibited by the environmental 
conditions. AvaII’s activity is blocked by overlapping dcm methylation. CD14 
restriction had no problems with dcm methylation. [82] 
 
The original base pair for the CD14 gene is the C allele. When the original allele is 
present, the sequence will read GGCCC, and because the enzyme can only recognize 
a G’GA(T)CC pattern, there will be no recognition site for the enzyme to ligate, 
resulting in the original 497 bp fragment.. However, when the polymorphic T allele is 
present, the resulting sequence would read GGTCC, and thus providing the 
recognition sequence of G’GTCC for the enzyme to ligate and produce the fragment 
sizes shown in Figure 4.1 and listed in Table 4.1 
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 Table 4.1: Results of RFLP for CD14 Polymorphism, enzyme used and the fragment 
sizes. 
Polymorphism RE / TempoC Allele Fragment size 




497, 353, 144 bp 
353, 144 bp 
Note: bp = Base Pair 
 
Figure 4.1: Restriction digest photo of the CD14 -159 C/T polymorphism as viewed on a 
2% ethidium bromide stained agarose gel. 
 
T/T T/T T/T T/T C/T C/T C/T C/C C/C
Note: 
M = Marker (GeneRulerTM 50bp DNA Ladder Plus (MBI Fermentas) 
1-9 = Samples 1 to 9 
UC = Uncut 
C = Cut 
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 A tabulated table showing the observed numbers present in each genotype in both the 
controls and affected population is listed in Table 4.2. The table also lists the expected 
frequencies as well as the allelic frequencies of the alleles. Calculation of Hardy 
Weinberg equation was applied and the population was found to be in equilibrium. Z-
score analysis revealed no association observed between the controls and affected at Z 
score = -1.91 (p>0.05) (Table 4.2). 
 
Allele frequencies as well as genotype frequencies were calculated and the results 
shown in Table 4.2. 
 
Comparison by percentage, T allele frequency appears to be higher in the controls 
than compared to the affected, whereas the C allele is the dominant allele in the 
affected population (Table 4.2). Comparing the two alleles within their individual 
groups shows the frequency of the T allele to be greater than the C allele in the 
control group. The same trend is also noted in the affected group where the T 
frequency is greater than the C frequency (Table 4.2) 
 
The CC and CT genotypes appear in a lower percentage in the control population 
(17.43%, 37.61% respectively), as opposed to the TT genotype at 44.95%. (Table 4.2). 
In the affected group, the CT heterozygote has the highest percentage (53.25%) as 
compared to the CC (19.48%) and TT (27.27%) (Table 4.2). 
 
Comparing genotypes within the individual groups, the TT genotype is again seen to 
be the dominant feature in the affected group (Table 4.2). 
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 The results obtained for the serum IgE levels in the patients do not reflect the nature 
of the published data, where TT genotype is related to low IgE levels. From results 
acquired, it is noted that the individuals carrying the CC and CT genotypes had 
similar IgE levels, as well as levels lower than the TT homozygous genotype (Table 
4.2).  
 
The geometric mean for total IgE in the control group is 24.77 IU/ml for CC 
homozygotes, 17.79 IU/ml for CT heterozygotes and 19.32 IU/ml for TT 
homozygotes (Table 4.2). For the affected individuals, the geometric mean for total 
IgE was 380.45 IU/ml for the CC genotype, 312.51 IU/ml for the CT genotype and 
419.28 IU/ml for the TT genotype (Table 4.2). 
 
The different genotypes did not bring about any significant differences in the mean 
total serum IgE levels within the control population (Table 4.2). In the affected 
population, the TT genotype showed the highest serum total IgE levels, followed by 
both the CC and CT genotypes. As opposed publications by Baldini et al’s group [39], 
the local Chinese population in Singapore showed that the most common genotype in 
the affected group is the CT genotype. One interesting point to note is that the variant 
TT homozygous genotype yielded the higher levels of IgE as compared to the normal 
allele. This is contrary to the results obtained by Baldini et al, which showed that 
individuals harboring the TT genotype having the lowest IgE levels compared to 
individuals with the other genotypes. 
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  Table 4.2: CD14 C/T polymorphism results for atopy and total IgE. 
Χ2
Population (n) CC CT TT C T
Chinese Normals (109) obs 19 (17.43%) 41 (37.61%) 49 (44.95%) 3.77 NS 0.36 0.64 -1.91  (p>0.05) NS
exp 14.31 50.37 44.31 0.36 0.64
IgE GM 24.77 17.79 19.32
Range (2.18 - 102.96) (0.82 - 113.75) (1.12 - 116.13)
Chinese Affected (77) obs 15 (19.48%) 41 (53.25%) 21 (27.27%) 0.39 NS 0.46 0.54
exp 16.37 38.27 22.37 0.46 0.54
IgE GM 380.45 312.51 419.28
Range (180.99 - 1580.89) (105.42 - 3968.96) (136.235 - 2961.46)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Genotype frequency Allele frequency
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)






 4.2  IL-12 Promoter, Exons 6, 7 and Exon 8 1188 A/C Polymorphism. 
 
A total number of 90 unrelated controls and 93 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the IL-12 1188 A/C 
polymorphism.  
 
Sequencing on a total number of 90 unrelated controls and 93 unrelated affected 
individuals was carried out on the IL-12 promoter region, exons 6, 7 and 8. However, 
no polymorphisms were found within the regions sequenced for the promoter, exons 6 
and 7 (data not shown). The polymorphism 1188 A/C, found within the 3’untranslated 
region of the IL-12 exon 8 gene, was the focus of the study. Sequencing was not done 
on exons 1 to 5 as these regions were short and there were no reported polymorphisms 
present in any of the exons. 
 
Sequencing of IL-12 exon 8 was done using the reverse primer (Table 3.7). Therefore, 
the genotype appearing in Figure 4.2 would reflect the complementary base pairs. 
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 Figure 4.2: Sequencing of IL-12 1188A/C Polymorphism. 
     
IL-12 1188 A/A   IL-12 1188 A/C  IL-12 1188 C/C 
Homozygous   Heterozygous   Homozygous 
 
The product of the IL-12 RFLP PCR was a 233bp fragment. Restriction enzyme used 
for identification of polymorphism was Taqα1. The enzyme was obtained from an E. 
coli strain that carried a Taqα1 overproducing plasmid. Taqα1 has two amino acid 
replacements at its amino terminus, and this facilitates a higher level of expression 
with interference with its catalytic properties [82]. For this particular enzyme to 
obtain maximum efficiency, presence of BSA (Bovine Serum Antigen) is essential. 
Incubation of the enzyme without BSA would result in a decrease of 50% activity 
[82]. The enzyme’s active temperature is 65oC, at 80oC for 20 minutes it would be 
rendered inactive. Taqα1’s activity can be blocked by overlapping dam methylation 
[82], which fortunately was not a problem in our study.  
 
The sequence of recognition is 5’- T’CGA –3’ and 3’– AGC’T –5’. Original sequence 
is 5’– TAGA -3’. In the presence of the polymorphic C allele, a recognition pattern is 
established for the restriction enzyme to cut, resulting in the respective fragment sizes 
(Table 4.3, Figure 4.3). 
  
 56
 Table 4.3: Results of RFLP for IL-12 Polymorphism, enzyme used and the fragment 
sizes. 
Polymorphism RE / TempoC Allele Fragment size 




233, 165, 68 bp 
165, 68 bp 
 
Figure 4.3: Restriction digest photo of the IL-12 1188 A/C polymorphism as viewed on a 
2% ethidium bromide stained agarose gel. 
 
Note: 
M = Marker (GeneRulerTM 50bp DNA Ladder Plus (MBI Fermentas) 
1-7 = Samples 1 to 7 
UC = Uncut 
C = Cut 
 
The results were tabulated to show the observed numbers present in each genotype in 
both the controls and affected population (Table 4.4). Table 4.4 also highlights the 
expected and observed allelic frequencies. Calculation of Hardy Weinberg equation 
was applied and the population was found to be in equilibrium at alpha > 0.05. 
Results are found in Table 4.4. Z-score analysis applied also revealed no association 
observed between the controls and affected at Z score = -1.87 (p>0.05) (Table 4.4). 
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 The allele and genotype frequencies were calculated and tabulated in Tables 4.4. As 
seen from the tables, the percentage of the A allele is the highest in the affected 
population at 60.22% (Table 4.4). Within the control group, the A and C allele are in 
almost equal distribution. The controls are seen to have an almost equal distribution of 
the A and C allele, as compared to the affected, which shows a higher percentage of A 
over C allele.  
 
The A/A and C/C genotypes in the controls are almost equal (27.78% and 26.67% 
respectively) (Table 4.4). In the affected group, the C/C genotype has a lower 
percentage (19.35%) and almost equal distribution of the A/A and A/C genotypes 
(Table 4.4). 
 
Geometric mean for total serum IgE was calculated, and the control population 
showed no difference between the various genotypes and the level of serum total IgE 
(Table 4.4). In the affected population however, there appears to be a tendency 
towards a higher serum total IgE level in homozygous A/A genotypes (Table 4.4). 
However, all these results yield a lack of association statistically when calculated 
using the Chi Square and Z-score calculations (Table 4.4). 
 58
  Table 4.4: IL-12 3’UTR 1188 A/C polymorphism results for atopy and total IgE. 
Χ2
Population (n) AA AC CC A C
Chinese Normals (90) obs 25 (27.78%) 41 (45.56%) 24 (26.67%) 0.71 NS 0.51 0.49 -1.87  (p>0.05) NS
exp 23 44.99 22 0.51 0.49
IgE GM 19.17 21.41 20.39
Range (1.21 - 41.00) (0.82 - 57.34) (0.62 - 46.98)
Chinese Affected (93) obs 37 (39.79%) 38 (40.86%) 18 (19.35%) 2.02 NS 0.6 0.4
exp 33.72 44.56 14.72 0.6 0.4
IgE GM 1276 795.21 840
Range (100.99 - 21897.20) (125.00 - 9188.71) (105.94 - 3950.16)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Genotype frequency
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Allele frequencyp-value




 4.3  IL-13 Polymorphisms. 
 
4.3.1 IL-13 -1512 A/C Polymorphism. 
 
A total number of 109 unrelated controls and 79 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the IL-13 -1512 A/C 
polymorphism (Table 4.5). 
 
A prior study employed RFLP as a means of identifying the polymorphism. However, 
as there were no specific digestion sites on or around the polymorphic region, a site 
directed mutagenesis was conducted (Table 3.6) to create a recognition site. However, 
this method did not produce the desired repeatable results, and thus after multiple 
unsuccessful attempts at separating the bands, it was decided that the best and fastest 
way to identify the respective polymorphisms was via sequencing. Sequencing was 
carried out on all 109 unrelated controls and 79 unrelated affected individuals. This 
enabled a clearer and more concrete evidence of the presence of the polymorphisms 
present (Figure 4.4). 
 
The area where the site directed mutagenesis was carried out lies two base pairs 
downstream from the polymorphic site. From the sequencing pictures shown in Figure 
4.4, it can be seen that the procedure gave unrepeatable base pair changes, and thus 
the reason why RFLP was not able to produce repeatable results. 
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 Figure 4.4: Sequencing of IL-13 -1512 A/C Polymorphism. 
        
IL-13 -1512 A/A  IL-13 -1512 A/C      IL-13 -1512 C/C  
Homozygous   Heterozygous       Homozygous 
 
The results obtained via sequencing were tabulated and presented in Table 4.5. The 
table also highlights the expected and allelic frequencies. Hardy Weinberg equation 
was calculated and the population was found to be in equilibrium at alpha > 0.05 
(Table 4.5). Z-score analysis applied also revealed no association observed between 
the controls and affected at Z score = 0.36 (p>0.05) (Table 4.5). 
 
The frequencies of both alleles and genotypes were calculated and presented in Table 
4.5. From the results obtained, it is noted the distribution of the A and C alleles 
between both the groups are almost similar. The genotype distribution also follows a 
comparable pattern (Table 4.5). 
 
Mean serum IgE levels were calculated for each genotype and graphed. From the 
results obtained, C/C genotype appeared to facilitate high serum total IgE levels, as 
compared to the A/A and A/C genotype (Table 4.5). No difference is noted between 
the various genotypes in the control group. 
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 Statistical analysis were conducted for association between genotypes and rhinitis, 






 Table 4.5: IL-13 -1512 A/C polymorphism results for atopy and total IgE. 
Χ2
Population (n) AA AC CC A C
Chinese Normals (109) obs 67 (61.47%) 35 (32.11%) 7 (6.42%) 0.67 NS 0.78 0.22 0.36  (p>0.05) NS
exp 65.51 37.99 5.51 0.78 0.22
IgE GM 21.17 17.54 12.67
Range (0.88 - 105.17) (0.82 - 116.13) (2.18 - 60.86)
Chinese Affected (79) obs 45 (59.96%) 30 (37.98%) 4 (5.06%) 0.12 NS 0.76 0.24
exp 45.57 28.86 4.57 0.76 0.24
IgE GM 369.52 356.87 450.11
Range (105.42 - 2961.46) (125.00 - 3968.96) (126.93 - 3249.10)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 4.3.2 IL-13 -1112 C/T Polymorphism 
 
A total number of 109 unrelated controls and 79 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the IL-13 -1112 C/T 
polymorphism (Table 4.6). 
 
Prior identification via RFLP was also used (Table 3.6). However, this polymorphism 
also failed to have an original recognition site, and one had to be created via the same 
procedure of site directed mutagenesis. This method also did not produce consistent 
results and thus direct sequencing was applied to all 109 unrelated controls and 79 
unrelated affected individuals (Figure 4.5). 
 
Again, the engineered base pair change lies two base pairs downstream from the 
polymorphic site. From the sequencing pictures shown in Figure 4.5, it can be seen 
that the procedure produced a heterozygous base pair, and thus identification via 
RFLP was not useful. 
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 Figure 4.5: Sequencing of IL-13 -1112 C/T Polymorphism. 
        
IL-13 -1112    IL-13 -1112 C/T      IL-13 -1112 T/T 
Homozygous   Heterozygous       Homozygous 
 
Hardy Weinberg equilibrium was applied to the tabulated results and the population 
was found to be in equilibrium at alpha > 0.05 (Table 4.6). Z score statistical analysis 
was conducted and no significant associations were obtained (Z score = 0.62, p > 0.05) 
(Table 4.6). 
 
The distribution of the alleles between the control and affected groups are similar at 
85.35% and 82.91% respectively for the C allele and 14.68% and 17.09% for the T 
allele (Table 4.6). Genotype distribution between the control and affected populations 
are again similar at 70.64% and 67.09% for the C/C genotype; 29.36% and 31.65% 
for the C/T genotype respectively (Table 4.6). However, there was no T/T genotype 
individuals observed in the control population (Table 4.6). Taking into account that 
the T/T genotype frequency in the affected population was 1.27%, the lack of T/T 




 Serum IgE levels does not appear to have a significant difference between control 
individuals carrying the C/C or C/T genotype (Table 4.6). A similar trend is found in 
the affected individuals, where the C/C and C/T genotypes hover at 347.14 IU/ml and 
435.79 IU/ml respectively (Table 4.6). However the results obtained are not a true 
reflection of the overall data, reason being that there is a statistical singleton in the 
T/T genotype of the affected population (Table 4.6). Thus results can only be 
compared between the C/C and C/T genotypes of each population, and this result 
suggests that there is no significant association between serum IgE and the respective 
genotypes in either population (Table 4.6). 
 
Association between genotypes and rhinitis, dermatitis and asthma were also 
statistically analyzed using the Z-score analysis. However, no significant associations 





 Table 4.6: IL-13 -1112 C/T polymorphism results for atopy and total IgE. 
Χ2
Population (n) CC CT TT C T
Chinese Normals (109) obs 77 (70.64%) 32 (29.36%) 0 (0%) 3.23 NS 0.85 0.15 0.63  (p>0.05) NS
exp 79.35 27.3 2.35 0.85 0.15
IgE GM 19.54 19.44 0
Range (0.88 - 116.13) (0.82 - 97.52) (0-0)
Chinese Affected (79) obs 53 (67.09%) 25 (31.65%) 1 (1.27%) 1.08 NS 0.83 0.17
exp 54.31 22.39 2.31 0.83 0.17
IgE GM 347.14 435.79 126.93
Range (105.42 - 2961.46) (125.00 - 3968.96) (126.93 - 126.93)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 4.3.3 IL-13 +1923 C/T Polymorphism. 
 
A final number of 111 unrelated controls and 79 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the IL-13 +1923 C/T 
polymorphism (Table 4.8). 
 
Restriction digest for the IL-13 +1923 C/T polymorphism was possible and the results 
are shown in Table 4.7, Figure 4.6. 
 
Sequencing was also carried out the polymorphism in all 111 unrelated controls and 
79 unrelated affected individuals to reconfirm the polymorphism as well as the 
digested products were of the correct fragments (Figure 4.7). 
 
Table 4.7: Results of RFLP for IL-13 Polymorphisms, enzymes used and the fragment 
sizes 
Polymorphism RE / TempoC Allele Fragment sizes 




559, 310, 249 
559 
Note: RE = Restriction Enzyme 
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 Figure 4.6: Restriction digest photo of the IL-13 +1923 C/T polymorphism as viewed on 
a 2% ethidium bromide stained agarose gel. 
 
Note: 
M = Marker (GeneRulerTM 50bp DNA Ladder Plus (MBI Fermentas) 
1-7 = Samples 1 to 7  
UC = Uncut 
C = Cut 
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 Figure 4.7: Sequencing of IL-13 +1923 C/T Polymorphism. 
     
IL-13 +1923     IL-13 +1923 C/T   IL-13 +1923 T/T 
Homozygous    Heterozygous    Homozygous 
 
The population was in Hardy Weinberg equilibrium at alpha > 0.05 (Table 4.8). Z 
score statistical analysis was conducted resulted in a non significant association (Z 
score = 1.08, p > 0.05) (Table 4.8). 
 
Allele frequency for the control and affected groups for C allele was 68.02% and 
62.66%, and for the T allele 31.98% and 37.34% respectively (Table 4.8). There were 
no significant difference between the distribution of alleles between the control and 
affected groups. Genotype distribution between affected and control groups showed 
that the TT genotype was more prevalent in the affected group as compared to the 
control group at 18.99% to 10.81% respectively (Table 4.8). However the genotype 
frequency does not translate to statistical significance (Table 4.8).  
 
Statistically the various genotypes do not seem to affect the geometric mean for total 
serum IgE levels of the individuals from either the control or affected group (Table 
4.8). It appears that neither any of the genotypes confer susceptibility for high or low 
IgE levels. 
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 The various genotypes also do not appear to have any significant associations with the 
phenotypic manifestations of rhinitis, dermatitis and asthma (Table 4.8). 
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 Table 4.8: IL-13 +1923 C/T polymorphism results for atopy and total IgE. 
Χ2
Population (n) CC CT TT C T
Chinese Normals (111) obs 52 (46.85%) 47 (42.34%) 12 (10.81%) 0.08 NS 0.68 0.32 1.08  (p>0.05) NS
exp 51.35 48.29 11.35 0.68 0.32
IgE GM 17.76 18.12 45.04
Range (0.88 - 116.13) (0.82 - 98.14) (14.67 - 113.75)
Chinese Affected (79) obs 35 (44.30%) 29 (36.71%) 15 (18.99%) 3.67 NS 0.63 0.37
exp 31.02 36.97 11.02 0.63 0.37
IgE GM 374.54 389.77 317.51
Range (108.74 - 3968.96) (105.42 - 3249.14) (125.00 - 1755.06)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 4.3.4 IL-13 +2044 G/A Polymorphism. 
 
A final number of 111 unrelated controls and 79 unrelated affected individuals with 
known IgE levels and atopic status were included in the study of the IL-13 +2044 G/A 
polymorphism (Table 4.9). 
 
The IL-13 +2044 G/A polymorphism had no direct recognition site for enzyme 
digestion, and thus direct sequencing was applied to all the 111 unrelated controls and 
79 unrelated affected individuals PCR product, and the results are shown in Figure 4.8. 
 
Figure 4.8: Sequencing of IL-13 +2044 G/A Polymorphism. 
    
IL-13 +2044 G/G   IL-13 +2044 G/A   IL-13 +2044 A/A 
Homozygous    Heterozygous    Homozygous 
 
The population was in Hardy Weinberg equilibrium at alpha > 0.05 (Table 4.9). Z 
score statistical analysis was conducted resulted in a non significant association (Z 
score = 1.30, p > 0.05) (Table 4.9). 
 
Allele frequency for the G allele was 68.47% and 62.03% respectively for the controls 
and affected, and 31.53%, 37.97% respectively for the A allele (Table 4.9). There 
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 were no significant difference between the distribution of alleles between the control 
and affected groups. Genotype distribution between affected and control groups 
showed that the TT genotype was slightly more prevalent in the affected group as 
compared to the control group at 17.72% to 11.71% respectively (Table 4.9). 
However the genotype frequency does not translate to statistical significance (Table 
4.9).  
 
Different genotypes do not appear to have any effect on the serum IgE levels of the 
individual and statistical analysis also showed no significant association (Table 4.9).  
 
The +1923 and +2044 polymorphism are also noted to be in almost total linkage 
disequilibrium (delta = 0.99). As such, results also showed no significant associations 
with the traits of rhinitis, dermatitis and asthma (Table 4.9) 
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 Table 4.9: IL-13 +2044 G/A polymorphism results for atopy and total IgE. 
Χ2
Population (n) GG GA AA G A
Chinese Normals (111) obs 54 (48.65%) 44 (39.64%) 13 (11.71%) 0.75 NS 0.68 0.32 1.3  (p>0.05) NS
exp 52.04 47.93 11.04 0.68 0.32
IgE GM 18.38 16.76 47.51
Range (0.88 - 116.13) (0.82 - 98.14) (14.67 - 113.75)
Chinese Affected (79) obs 33 (41.77%) 32 (40.51%) 14 (17.72%) 1.55 NS 0.62 0.38
exp 30.39 37.22 11.39 0.62 0.38
IgE GM 389.26 368.33 323.33
Range (108.74 - 3968.96) (105.42 - 3249.14) (125.00 - 1755.06)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 4.3.5 IL-13 +4738 G/A, +4793 C/A and +4962 C/T Polymorphism. 
 
A total of 106 unrelated controls and 78 unrelated affected individuals with known 
IgE levels and atopic status were included in the study of the 3 IL-13 3’UTR 
polymorphisms  +4738 G/A, +4793 C/A and +4962 C/T polymorphisms (Tables 4.10 
– 4.12). 
 
These three 3’ UTR polymorphisms were studied in all 106 unrelated controls and 78 
unrelated affected individuals by sequencing using the same reverse primer (Table 
3.9), and thus the genotype appearing in the sequenced products are all in the 
complementary base pairs (Figures 4.9 – 4.11).  
 
Figure 4.9: Sequencing of IL-13 +4738 G/A Polymorphisms. 
     
IL-13 +4738 G/G   IL-13 +4738 G/A   IL-13 +4738 A/A 
Homozygous    Heterozygous    Homozygous 
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 Figure 4.10: Sequencing of IL-13 +4793 C/A Polymorphism 
     
IL-13 +4793     IL-13 +4793 C/A  IL-13 +4793 A/A 
Homozygous    Heterozygous   Homozygous 
 
Figure 4.11: Sequencing of IL-13 +4962 C/T Polymorphism 
     
IL-13 +4962    IL-13 +4962 C/T   IL-13 +4962 T/T 
Homozygous   Heterozygous    Homozygous 
 
The populations were in Hardy Weinberg equilibrium at alpha > 0.05 (Table 4.10 – 
4.12). Z score statistical analysis conducted showed no significant association at a 
value of 1.36, p > 0.05 (Tables 4.10 – 4.12). 
 
Allele frequency for the control and affected groups for C allele was 68.40% and 
61.54%, and for the T allele 31.60% and 38.46% respectively. There were no 
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 significant difference between the distribution of alleles between the control and 
affected groups (Tables 4.10 – 4.12).  
 
Genotype distributions between affected and control groups also showed that the 
variant genotypes of each group was more prevalent in the affected group as 
compared to the control group at 19.23% to 11.32% respectively (Tables 4.10 – 4.12). 
However, as before, the results are not translated to statistical significance (Tables 
4.10 – 4.12). 
Geometric mean serum IgE levels were calculated for each genotype. Results do not 
demonstrate any significant association of genotype with levels of serum IgE within 
the individuals from the control or affected population. Thus a suggestive conclusion 
that neither genotype confers susceptibility to high or low IgE can be drawn from it 
(Tables 4.10 – 4.12).  
 
However, one observable association made is that the 3’ UTR polymorphisms are 
seen to be in total linkage disequilibrium at delta = 1. The IL-13 +1923 and +2044 
polymorphisms are also seen to be in linkage disequilibrium with the 3’UTR 
polymorphisms. 
 
All three 3’UTR polymorphisms also exhibited no significant associations with 
phenotypic traits of rhinitis, dermatitis and asthma (Tables 4.10 – 4.12). 
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 Table 4.10: IL-13 +4738 G/A polymorphism results for atopy and total IgE. 
Χ2
Population (n) GG GA AA G A
Chinese Normals (106) obs 51 (48.11%) 43 (40.57%) 12 (11.32%) 0.4 NS 0.68 0.32 1.36  (p>0.05) NS
exp 49.59 45.83 10.59 0.68 0.32
IgE GM 17.74 16.72 45.04
Range (0.88 - 116.13) (0.82 - 98.14) (14.67 - 113.75)
Chinese Affected (78) obs 33 (42.31%) 30 (38.46%) 15 (19.23%) 2.74 NS 0.62 0.38
exp 29.54 36.92 11.54 0.62 0.38
IgE GM 389.26 381.29 317.51
Range (108.74 - 3968.96) (105.42 - 3249.14) (125.00 - 1755.06)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 Table 4.11: IL-13 +4793 C/A polymorphism results for atopy and total IgE. 
Χ2
Population (n) CC CA AA C A
Chinese Normals (106) obs 51 (48.11%) 43 (40.57%) 12 (11.32%) 0.4 NS 0.68 0.32 1.36  (p>0.05) NS
exp 49.59 45.83 10.59 0.68 0.32
IgE GM 17.74 16.72 45.04
Range (0.88 - 116.13) (0.82 - 98.14) (14.67 - 113.75)
Chinese Affected (78) obs 33 (42.31%) 30 (38.46%) 15 (19.23%) 2.74 NS 0.62 0.38
exp 29.54 36.92 11.54 0.62 0.38
IgE GM 389.26 381.29 317.51
Range (108.74 - 3968.96) (105.42 - 3249.14) (125.00 - 1755.06)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 Table 4.12: IL-13 +4962 C/T polymorphism results for atopy and total IgE. 
Χ2
Population (n) CC CT TT C T
Chinese Normals (106) obs 51 (48.11%) 43 (40.57%) 12 (11.32%) 0.4 NS 0.68 0.32 1.36  (p>0.05) NS
exp 49.59 45.83 10.59 0.68 0.32
IgE GM 17.74 16.72 45.04
Range (0.88 - 116.13) (0.82 - 98.14) (14.67 - 113.75)
Chinese Affected (78) obs 33 (42.31%) 30 (38.46%) 15 (19.23%) 2.74 NS 0.62 0.38
exp 29.54 36.92 11.54 0.62 0.38
IgE GM 389.26 381.29 317.51
Range (108.74 - 3968.96) (105.42 - 3249.14) (125.00 - 1755.06)
NS: Not significant at α = 0.05
obs = observed
exp = expected
IgE GM = IgE Geometric Mean
Hardy - Weinberg 
equilibrium
Allele frequency comparison 
between controls and atopics  
Z-score (p-value)Genotype frequency p-value Allele frequency
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 5 Discussion 
 
Asthma and allergic diseases are not only a strain on the economic resources of a 
nation, but also a potential health risk to the individual. In the past 30 years, there has 
been a steady increase in the cases of childhood asthma, from an initial rate of 3.8% in 
1967 to 14.7% in 1987 and to 20% in the year 1995. The death rates from asthma 
stand at an annual figure of 5 deaths per 100,000 individuals [6]. Singapore has a 
population of 2.8 million, and out of these, the approximate figures of those who are 
afflicted with asthma stand at a rate of 5% [6]. The economic quandary of this health 
predicament would cost tax payers an approximate sum of US$17.22 million for both 
medical and healthcare costs [83]. 
 
The clinical expression of atopy can be manifested as asthma, a wide range of 
allergies, eczema or rhinoconjunctivities. These symptoms are almost always 
accompanied by an increase in total serum IgE levels [84]. Although total IgE 
determination is a crude method for screening, it is able to predict a predisposition to 
atopy. Normal levels of serum IgE do not rule out the presence of atopic disease while 
elevated levels may in 20- 30% of instances not be associated with atopic disease. 
Therefore it is difficult to define an exact cutoff level that would indicate atopy. 
However, it is justifiable to deem that the higher the serum total IgE, the more likely 
the presence of atopy. In children it has been shown that geometric mean IgE levels 
rose in association with different allergic disease states (8). The highest levels 
occurred in patients with atopic dermatitis associated with respiratory allergy (8).  
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 Asthma and atopy also both fall under the category of complex genetic diseases, as 
such; they do not exhibit classical Mendelian patterns of inheritance and genetically 
involve multiple genes which interact in complex ways with various environmental 
factors [85]. To complicate matters, the genes that are involved in the pathogenesis of 
asthma and atopy are different from those that regulate the presence of increased 
levels of both serum total and specific IgE [84]. 
 
In general, two methods have been used to investigate the molecular genetics of 
asthma, and they are: the candidate gene approach and the whole genome screens 
followed by positional cloning [85]. Candidate gene study was carried out on 
chromosome 5q by other members in the group [30] and LOD scores revealed that the 
region showed evidence of linkage of the asthma and atopy phenotypes with three 
markers [30]. These microsatellite markers spanned a distance of 41cM along the 
chromosome, and comprised of D5S2110, D5S2011 and D5S412 (P values of 0.001 
to 0.00001). LOD stands for “log of odds” [86] and is a method to obtain reliable 
recombinant frequency values.  
 
The principle of the method calculates the probability of obtaining a set of results in a 
family on the basis of independent assortment and a specific degree of linkage [76, 
86]. This marker, especially marker D5S412, was located near the gene coding for IL-
12b, the inducer of T-cells to produce interferon-gamma [82]. Presence of a 
polymorphism in this region may affect the interplay between the Th-1 and Th-2 cells. 
The marker D5S2110 is located near the IL-4 and IL-13 cluster of genes encoding the 
Th-2 cytokines [82]. The prior study (data unpublished) documented that marker 
D5S2011 was close to the IL-9 cytokine region, and IL-9 has been shown to play a 
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 role in the regulation of IgE synthesis in man [82]. However, the study (unpublished 
data, Tan and Tay) also did not find any information about the IL-9 polymorphic 
marker in our Chinese population [82].  
 
From this prior linkage study, the field on interest and study was narrowed down to 
the CD14, IL-12 and IL-13 genes. 
 
5.1 CD14 Polymorphism and its resulting impact and effect. 
 
As observed from two previous studies, CD14 was found to have an association with 
serum total IgE levels [38, 40]. The groups found that the T/T homozygous genotype 
had significantly lower levels of IgE than did individuals who harbored either 
genotype [40]. However this result was only applicable when the T/T homozygous 
individuals were SPT positive to local aeroallergens [40].  
 
However, this phenomenon was not replicated in our local population. There were no 
significant associations detected between serum total IgE and their respective 
genotypes. Frequency of the C and T alleles in our local control population did 
demonstrate that the T allele had a higher frequency (63.76%) as compared to the C 
allele (36.24%) (Table 4.2). This was also reflected in the affected individuals, where 
the T allele stood at a value of 53.90% vs. the C allele at 46.10% (Table 4.2). 
 
Baldini’s study showed that individuals harboring the T/T homozygous genotypes 
were noted to have lower levels of IgE. From results obtained in our study, the 
frequency of the T allele in our control population was in a higher percentage as 
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 compared to that in the affected population, suggesting the phenomenon that the T 
allele would confer a lower serum IgE level and thus confer certain protective value to 
the individual. However, statistical analysis did not show this association (Table 4.2). 
 
The different genotypes did not bring about any significant differences in the 
geometric mean for total serum IgE levels within the control population. In the 
affected population, the T/T genotype showed the highest serum total IgE levels, 
followed by the C/C then the C/T genotype (Table 4.2). Interestingly, the local 
Chinese population in Singapore showed that the most common genotype in the 
affected group is the T/T genotype. One interesting point to note is that homozygous 
T/T genotype yielded the highest levels of IgE as compared to the other two 
genotypes. This is contradictory to the results that Baldini et al obtained, which 
showed that the T/T homozygous individuals had the lowest serum IgE levels [40]. 
 
We did not observe an association with atopy, and this result is again backed by Woo 
et al, who found that within their study, CD14 was not associated with the presence of 
atopy [36]. 
 
However, percentage wise, we do see that the genotype T/T, within the control group 
is the highest (Table 4.2). However, statistically, it yields a lack of association (Table 
4.2). If the T/T genotype is related to low IgE, and that the C/C and C/T genotype has 
a predisposition to higher IgE, then we could possibly say that within the control 
group, this phenomenon is noted, as the presence of the T/T homozygous is the 
highest, followed by the heterozygous C/T. Unfortunately, this finding has not proven 
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 to be statistically significant, and as such, no conclusive conclusion can be made 
about the polymorphism in relation to atopy and total serum IgE levels. 
 
One other plausible reason why there are no significant associations in our population 
is that the CD14 polymorphism might play a more important role in atopy 
development and regulation of serum IgE level in children than in adults. In both 
reports from Baldini et al and Woo et al [36, 40], the study was carried out mainly on 
children, whereas our local population consisted mainly of adults. A recent paper by 
O’Donnell [87] found that the CD14 -159 C/T polymorphisms was associated with 
increased odds of childhood atopy and airway hyper responsiveness, and that this 
association was only seen in mid-childhood but not adulthood [87] supported this 
train of thought. 
 
5.2 IL-12 Polymorphism and its resulting impact and effect. 
 
Effort put in by Hall et al [71] identified via bioinformatics strategy, the first IL-12 
1188 A/C polymorphism. They aligned cDNA and expressed sequence tags (EST) 
from multiple independent Gen Bank entries and demonstrated that this region was 
polymorphic with the frequency of the common allele at approximately 80% of 
healthy UK Caucasoids [71]. 
 
Later studies revealed that there are further polymorphisms present in the IL-12 
receptor and gene [47, 88] and together with the information that we gathered 
previously about the LOD scores of IL-12 and the region where it lies on chromosome 
5q, prompted our own study into the IL-12 1188 A/C polymorphism. Initial studies 
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 associated the IL-12 1188 A/C polymorphism with type 1 diabetes susceptibility [89]. 
In the report, they demonstrated that this single base change in the 3’ untranslated 
region (UTR) showed strong linkage disequilibrium with the T1D susceptibility locus, 
as well, they also demonstrated that expression levels of IL-12 resulted as the 
presence of this particular polymorphism [89].  
 
It has been shown that IL-12 has a role to play in priming the immune system towards 
the Th-1 response. Hypothetically, since INFγ, produced by the IL-12 is able to affect 
the production of IgE, would not therefore a polymorphism present in the IL-12 gene 
or receptor result in deficiencies in IL-12, leading to a decreased IL-12 production and 
thereby favoring the move towards a Th-2 pattern and thereby a bias towards atopy 
and allergy.  
 
In our study, we looked at the association of the IL-12 polymorphism in association 
with total serum IgE, and atopic status of patients versus controls. Our results were in 
HWE (Table 4.4) and did not yield a significant association with the total serum IgE 
levels nor with atopic status (Table 4.4). Two separate groups conducted studies on 
the same polymorphism, but looking at aspects of severity of the atopic and non-
atopic disease presentation [90] and susceptibility to atopic dermatitis and psoriasis 
vulgaris [91]. The first group headed by Morahan et al [90] concluded that the 
polymorphism posed a potential role in the pathogenesis of asthma in humans, and 
that individuals who are heterozygous for the polymorphism stand at an increased risk 
for progression to severe asthma [90]. However, they also noted that although it has 
association with severe asthma, there are no indications for its involvement with mild 
or moderate disease, thereby leaving a question to the key genes involved in asthma 
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 and not atopy per se [90]. In our study, we are unable to draw a parallel with the 
results on the asthmatic status, but we were able to note that that the polymorphism 
also did not yield a significant association in our population (Table 4.4). This point 
has been backed by Morahan’s group it was also noted that there were no significant 
association between the promoter heterozygosity and any of the indices of atopy and 
concluded that the polymorphism was associated mainly with asthma severity and not 
with atopic status [90]. 
 
This finding was compounded by Tsunemi et al, where they found that the SNP was 
related to atopic dermatitis (AD) and psoriasis vulgaris (PsV) [91]. They showed that 
the normal allele A was decreased in AD patients (40.9%, p = 0.031) [91], and 
increased in PsV patients (60.1%. p = 0.035) [91] as compared to controls at 50.5% 
[91]. They hypothesized that the 1188 A/C SNP could possibly play a genetic role in 
AD and PsV [91]. 
 
One consistent finding however that was noted between all the groups including ours 
is that there appears to be no genetic association between the 1188 A/C SNP and that 
of serum IgE levels, allergic rhinitis or asthma [88, 90, 91]. 
 
One unusual feature of the IL-12 gene is that both its 5’ and 3’ ends have untranslated 
exons, thus, translation from its corresponding mRNA would start at the first codon of 
exon 2 and would terminate at the last codon of exon 7 [92]. The β2 subunit is 
essential for IL-12 signaling and its expression is highly regulated [93]. 
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 To date, although studies conducted have shown that there are possibilities of 
association of the IL-12 promoter polymorphism and severity of asthma, AD and PsV, 
there is no conclusive evidence that supports a positive association of the SNP and 
total IgE, atopy and asthma. However, mounting evidence has been building for an 
association for another cytokine, IL-13, its polymorphisms and the phenotype of 
atopy and asthma. This train of thought was also reached by Wills-Karp et al [48]. 
 
5.3 IL-13 polymorphisms and serum total IgE levels 
 
As mentioned previously, IL-13 has been implicated numerous times in the 
pathogenesis and regulation of IgE production. Studies carried out by Graves et al [1] 
and Xin Liu et al, demonstrated that there were significant associations between the 
increased total serum IgE levels and the variants -1112C/T and +2044G/A of the IL-
13 gene [70]. Closer to our race, a study done on the Chinese atopic patients with 
allergic rhinitis by Min Wang et al [77] however also had findings which showed that 
there was a significant association of the IL-13 +2044 polymorphism and serum total 
IgE levels in the patients.  
 
Although these polymorphisms were seen within our population, but as opposed to 
their findings, our variants of the same polymorphisms failed to yield a significant 
association between increased levels of total serum IgE between the controls and 
affected subjects. However, our results are in support of another study conducted by 
Celedon J. C. et al [94] which showed that among 83 Costa Rican school children 
with asthma and their parents, there was no evidence of linkage between the variants 
of the +2044 polymorphism and total serum IgE levels. A study conducted on the 
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 Japanese population by Tsunemi Y et al [68] also showed that there was no significant 
difference between the different genotypes in the +2044 G/A polymorphism.  
 
Graves et al showed that the 2044 A/A genotype is strongly associated with increased 
serum IgE levels in 3 different populations (P = 0.000002) [1]. However, with 
reference to our results in Table 4.9, our local population does not conform to the 
same phenomenon as that of Grave’s population. The mean serum IgE level appears 
to be the lowest in the 2044 A/A genotype, as compared to the G/G genotype. In 
addition, Grave’s group claimed that other SNPs in close linkage with the 2044 G/A 
(Arg130Gln) polymorphism is associated with the development of elevated serum IgE 
phenotype [1]. In our population, the SNPs in close linkage with the 2044 SNP are the 
1923 C/T and 3’UTR polymorphisms. However we have noted that these 
polymorphisms do not appear to have any association with serum IgE levels (Tables: 
4.9 - 4.12).  
 
Although Graves have also shown that the -1112 promoter polymorphism has no 
association with IgE levels [1], a paper by Xin Liu et al [70] discussed that their 
findings suggest that the variants of the -1112 polymorphism as well as the 2044 SNP 
might play an important role on the total serum IgE production in German children 
[70]. However, like Grave’s study, we failed to see association of the -1112 SNP with 
IgE levels in our population (Table 4.7). 
 
The conflicting results obtained by different races and ethnic groups leads one to 
question the feasibility of using total serum IgE as a standard to indicate asthma and 
allergy. Serum total IgE levels have been as standard measurement that is clinically 
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 used to diagnose allergic disorders. However it is still a grey area as to the 
interpretation and extent that IgE levels may contribute to diagnosis. IgE levels under 
normal circumstances, is a tissue-bound molecule [95] and is present in only 
nanogram amounts, in equilibrium with that bound to mast cells, basophils and other 
cells [95]. It was through further testing by Ishizaka and Ishizaka that the design and 
commercialization of immunoassays for allergen-specific IgE were implemented [96].  
 
Cutoff ranges and definition of high serum IgE varies from country to country, 
clinician to clinician. Reports have indicated that while total serum IgE cannot be 
used to rule out the presence of allergy to corresponding allergens, it can aid as a part 
of routine diagnostic work in patients who are suspected of having allergic diseases 
[97]. The decision on what is defined as high and low serum total IgE is therefore left 
to the clinician. This could be one of the reasons why there is a variation in reports on 
the effect of the various polymorphisms on the serum total IgE levels in the subjects. 
Another possible reason could also be due to the matrix of genetic cum environmental 
factors within each racial/ethnic group. 
 
5.4 IL-13 polymorphisms and association with other phenotypic expressions of 
allergic diseases 
 
Rhinitis is defined as an inflammation or nasal irritation. Symptoms of irritation 
include runny nose, itching, sneezing and congestion in the nasal passage. There are 
two kinds of rhinitis, acute and chronic. The duration of an acute rhinitis is usually 
less than six weeks, and is normally induced by infections or chemical irritation. 
Chronic rhinitis is caused mainly by allergy or a host of other factors, amongst which 
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 are temperature changes, pollen, environmental factors. Allergic rhinitis is among one 
of the major public health problems that are arising in this era [77]. 
 
At present, there is a lack of studies and published data on IL-13 polymorphisms and 
allergic rhinitis in patients. To date, only one publication by Min Wang et al [77] 
regarding rhinitis and IL-13 has been documented. Their study showed a correlation 
between patients with allergic rhinitis and a link with serum total IgE [77].  
 
IL-13 plays a major role in the pathogenesis of atopic dermatitis in the Japanese [68]. 
Reports have demonstrated that the -2044 G/A polymorphism has significant 
association with increased incidences of atopy in the population, where the A allele 
was significantly increased in patients with atopic dermatitis (39.5%) as compared to 
controls (29.4%) (P=0.016) [69]. He J-Q [98] also mentioned that several papers have 
reported associations of the -1112 C/T, +2044 G/A and +4738 G/A polymorphisms 
with atopy and atopic phenotypes[1, 2, 70, 99]. However, their study did not find any 
association of the -1112 C/T polymorphism with atopy or atopic disease [98],  
 
Links have been shown between allergic asthma and the -1112 promoter 
polymorphism [1, 2, 99]. In the study by van der Pouw Krann [99], it was shown that 
only the -1112 TT genotype was associated with allergic asthma. Reports by He J-Q 
contradicted this finding [98]. We likewise, have also not been able to demonstrate an 
association between the IL-13 -1112 polymorphism and allergic asthma, rhinitis or 
eczema (data not shown). However our sample size for each of the categories were 
small and therefore no definitive conclusions could be drawn. 
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 5.5 Linkage Disequilibrium between the various IL-13 Polymorphisms 
 
The polymorphisms in the 3’ untranslated region (UTR) also identified in our local 
population were seen to be in complete linkage disequilibrium with each other as well 
as to +2044 (Gln110Arg) polymorphism further upstream. The remaining 
polymorphisms are not in linkage disequilibrium with each other or to the 3’ UTR 
SNPs. However, the results appear to show that the polymorphisms do not have any 
significant association with serum total IgE levels, rhinitis, dermatitis or allergic 
asthma. 
 
Linkage is a condition in which two or more genes do not exhibit independent 
assortment [76]. The genes or genetic loci are found on the same chromosome, and 
would tend to be transmitted together [79].  
 
Howard TD et al observed significant linkage disequilibrium between the -1112 
promoter polymorphism and the 3’ UTR SNP, and also between the +2044 
polymorphism and the 3’ UTR SNP [2]. Another group headed by Xin Liu [70] 
reported strong linkage disequilibrium between the -1112 C/T and +2044 G/A 
polymorphism. We did not see linkage disequilibrium between the -1112 
polymorphism and the 3’UTR SNPs. However, we did observe a linkage 
disequilibrium between the +1923, +2044 and 3’ UTR SNPs. Our results are also 
reflected in the study done by Graves et al [1], where they also demonstrated the 
+2044 polymorphism in almost complete linkage disequilibrium with respect to the 3 
polymorphisms in the 3’UTR and also a polymorphism in the third intron of IL-13 
+1923 [1]. Although these polymorphisms are not located in the consensus sequences 
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 which are known to regulate either gene splicing, expression or IL-13 mRNA stability, 





DNA from a total of 111 unrelated controls and 77 unrelated affected volunteers were 
used to screen the CD14, IL-12 and the 7 polymorphisms in the IL-13 gene. We found 
the CD14 polymorphism described by Baldini et al [40], the IL-12 polymorphism and 
the 7 polymorphisms described previously by Graves et al [1] and Howard et al [2] in 
our local population.  
 
All SNPs tested were found to be in Hardy-Weinberg equilibrium. 
 
The notion that allergy runs in the family has been around for a very long time, but 
yet, no one group has conclusively been able to come to an unanimous decision that it 
is indeed totally hereditary, or caused specifically by genetics. Though various aspects 
of research have been done, the causative factors surrounding asthma and allergy is 
indeed highly challenging. As its term implies, asthma and atopy is a multi-factorial 
disease. It is dependent upon both the genetics as well as environmental triggers.  
 
From the results obtained from this study, it is observed that genetical factors alone 
will not lead to the asthma and atopy phenotype, rather, what the predisposing factor 
appears to be is actually a combination of both the environment and genes. 
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 As well, each gene taken alone does not yield significant associations between 
genotypic and phenotypic manifestations. There are however, a few plausible 
thoughts as to the reason: one of which could be a matter of ethnicity. We note that 
there appears to be associations of the various SNPs with disease in the Caucasian 
groups as well as the groups in Japan and China. When comparing our data with that 
of the Caucasian study, there is definitely the element of ethnic differences and 
association.  
 
Environmental factors are known to play an important role in the triggering process. 
This could also take into account the famous controversial  “hygiene hypothesis” [100, 
101]. Strachan [101] proposed that from observations, declining family size, 
improved living conditions and increasing hygiene standards have allowed for a 
decrease in opportunistic cross infections in young children. This would ultimately 
lead to a decreased Th-1 and an increased Th-2 immune response, resulting in a more 
widespread clinical expression of atopic disease. However, various groups 
researching into this hypothesis have concluded differently [100]. It is, however clear, 
that a bias into the Th-1 immune pattern does result in a decreased susceptibility, for a 
mere fact that atopy and asthma are predisposed by a Th-2 response. So therefore, 
even if the “hygiene hypothesis” were discarded, the fact still lie that individuals with 
a greater Th-2 immune response are more susceptible to atopy and asthma as 
compared to Th-1 dominant immune patterned individuals.  
 
The method of diagnosis and classification of atopy, and the cutoff threshold for high 
and low values of total serum IgE would be another factor which would result in a 
different result obtained. Different research groups and investigators would give a 
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 different perspective of their diagnosis and cut off ranges, and this in turn would also 
allow for a differing result. Different stringencies in sample collection and 
classification would also in turn give rise to different interpretations of results and 
associations. Care has to be placed in producing each questionnaire and collection of 
specimen from the individual subject has to be conducted under similar or close to 
similar methods and stringent quality control. This would help to minimize the risk 
that non associations or associations for that matter are solely due to the genetics 
rather than due to error in sample handling and information collection. 
 
Sample size would also be a ground for a differing and lack of association. Statistical 
and genetic association studies require a large population size. Most research groups 
have sample sizes of greater than 100 subjects per class, and associations were noted 
when sample sizes were large, as compared to non-associations noted in small sample 




 6 Conclusion 
 
Former reports by various groups demonstrating significant association between the 
various polymorphisms present in IL-13 gene and the physical manifestations of 
asthma and allergic diseases failed to yield the same significance in our local Chinese 
population. Our results obtained for the local population deviates from that obtained 
by the Dutch, British, Italian and Japanese populations, where significant associations 
were obtained.  
 
Although we found linkage disequilibrium between the polymorphisms +1923, +2044 
(Gln110Arg) and the 3’UTR (+4738, +4793 and +4962) in our local population, but 
there were no association with total IgE levels, rhinitis, atopic dermatitis nor allergic 
asthma. 
 
Although it has been demonstrated numerous times in a host of different groups, that 
IL-13 does indeed play a major role in the pathogenesis of asthma and allergic disease, 
and that it could have a significant impact in elucidating allergen-induced asthma and 
subsequent treatments. Studies carried out on the local Chinese Singaporean 
population did not yield the same significance. A variety of factors could account for 
this phenomenon. Reasons ranging from ethnical diversity, environmental conditions, 
difference in definition and thresholds could also account for the different results 
obtained by different groups around the world. It was of interest to note that even with 
the Chinese, the results were markedly different. One would expect that the local 
Singaporean Chinese would have a genetic makeup that is slightly similar to that of 
the China Chinese, but from comparison of results between the two groups, this does 
 97
 not appear to be the case. Another probability that could be explored could be due to 
the lack of power for association. Our study recruited a small amount of individuals as 
compared to the other studies conducted. The sample sizes in studies that showed 
association between the polymorphisms and the phenotypes ranged in the hundred’s 
to thousands of participating subjects. The Costa Rican study [94] that showed no 
association with total serum IgE had a sample of below 100. This could be a factor 
that could be a hindrance in the study. Many other groups focusing on the same 
polymorphisms have also found a lack of association with these polymorphisms and 
their own populations. It would be worthwhile to have a more stringent definition and 
criteria, as well as a larger sample group size for a more accurate association study. 
 
A common problem that exists in genetic studies falls in the fact that most of the 
results obtained by one group cannot be translated or replicated in another group or 
study. This could arise due to multiple factors such as population stratification, ethnic 
and environmental attributes, mode of classification of groups such as age, race, 
gender, and even more importance aspects such as disease classification may play a 
role in the different results obtained by different groups. It also highlights that 
studying multi-factorial traits is best conducted in homogenous populations. Even 
apparently minute issues such as methodology of diagnosing and classifying the 
various diseases and symptoms end up playing a major role in the final analysis of 
genotype versus phenotype.  
 
It appears that environmental and lifestyle conditions do have an important role in the 
shaping process for the phenotypes of the T cell effectors, as well as being one of the 
determinants in the physical manifestation of asthma and allergic diseases. In light of 
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 the economic and physical burden that allergic diseases and asthma would cast on the 
society, it is indeed essential that the roles that IL-12. IL-13 and CD14 play in the 
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